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 Triple negative breast cancers (TNBCs) account for ~15-20% of 
human breast cancers in Western countries. TNBCs are associated with poor prognosis 
and a low five year survival rate due, in part, to high rates of tumor recurrence, multi-
drug resistance, metastasis, and therapeutic toxicity. Tumor initiating cells (TICs) or 
cancer stem cells (CSCs) are proposed to be responsible for the origin and maintenance 
of tumors as well as cancer recurrence, metastasis and drug resistance. Nutritionally-
based low- to non-toxic therapeutic nutrients that eliminate both bulk tumor cells (non-
TICs) and TICs have potential for prevention and treatment of primary and metastatic 
cancers, including TNBCs. Omega-3 fatty acid-docosahexaenoic acid (DHA) and 
certain vitamin E compounds [gamma- and delta- tocopherols (T and T) and 
tocotrienols (T3 and T3)], separately and in combination, were investigated for their 
ability to eliminate non-TICs and TICs in human TNBCs and the mechanisms of action 
were studied. DHA induced apoptosis in several human TNBC cell lines via activation 
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of endoplasmic-reticulum stress (ER stress) mediated C/EBP (CCAAT/enhancer binding 
protein) homologous protein (CHOP)/death receptor-5 (DR5) pro-apoptotic signaling 
involving caspases-8 and 9. DHA eliminated TICs as measured by elimination of 
aldehyde dehydrogenase active (ALDH
+
) population and inhibition of mammosphere 
formation. DHA eliminated TICs via suppression of phosphorylated Signal transducers 
and activators of transcription 3 (pStat-3) as well as downstream mediators cellular 
myelocytomatosis oncogene (c-Myc) and cyclin D1. SiRNA to Stat-3 reduced the 
number of ALDH
+
 TNBCs cells and reduced pStat-3, c-Myc, and cyclin D1 mediators, 
showing that Stat-3 is necessary for maintaining ALDH
+
 population and that c-Myc and 
cyclin D1 are downstream mediators of Stat-3. Studies also demonstrated that vitamin E 
compounds possess distinct anticancer activities.  For example, RRR--tocopherol 
(T) and synthetic vitamin E (all-rac-T) did not exhibit pro-apoptotic properties, but 
instead increased numbers of TICs as determined by increased ALDH
+ 
population and 
enhanced numbers of  mammospheres, as well as induced increased, rather than 
decreased, Stat-3 signaling; whereas, T, T, T3 and T3 exhibited both pro-apoptotic 
and anti-TIC properties. In summary, studies provide novel insights into therapeutic 
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Chapter 1    Introduction 
1.1 Triple negative breast cancer (TNBC) 
 
    Breast cancer is the most common type of cancer (excluding skin cancers) and the 
second leading cause of cancer death in American women [1]. 234,580 new cases and 
40,030 deaths from breast cancer are estimated in the United States for 2013 [1].  
     Breast cancer is a heterogeneous disease which is divided into 6 subtypes  [2]:  
i) luminal subtype A [estrogen receptor+ (ER+) and/or progesterone receptor (PR+),  
Human Epidermal Growth Factor Receptor 2 (HER2-)]; ii) luminal subtype B (ER+ 
and/or PR+, HER2+ ), iii) HER2+ subtype (ER-, PR-, HER2+); iv) normal like subtype 
(similar expression pattern to normal breast tissue); v) basal like subtype (ER-, PR-, 
HER2-), also called triple negative breast cancer (TNBC) and vi) claudin Low subtype 
(ER-, PR-, HER2-, claudin-, E-cadherin-, high expression of Epithelial–mesenchymal 
transition (EMT) [3]. Current treatments are surgery and radiation accompanied with 
chemotherapies and/or targeted therapies as an adjuvant. The treatments are effective at 
the beginning of therapy in 90% of primary breast cancers; however, tumor recurrence 
which is commonly associated with metastasis and drug resistance may occur [4].  
Secondary tumors and some breast cancer subtypes such as TNBC remain challenges for 
curing breast cancer.    
  ER and HER2 levels are used as predictive markers to select specific targeted 
therapies [5]. TNBC, classified within the basal like breast cancer subtype [6], is defined 
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by a lack of expression of both estrogen and progesterone receptors as well as human 
epidermal growth factor receptor 2 [6]. TNBC has a poor prognosis with a low 5-year 
survival rate [6] due to its aggressive clinical course and lack of specifically targeted 
therapy. It comprises 15-20% human breast cancer in Western countries [6]. Due to lack 
of molecular targets, chemotherapy remains the only choice for these patients [6]. DNA 
damaging drugs such as doxorubicin, cisplatin and taxol are used as standards-of-care. 
Although TNBC has been reported to be sensitive to chemotherapy initially, prognosis 
for this subtype of breast cancer remains poor due to tumor recurrence, drug resistance 
and chemotherapy toxicity [7, 8]. Therefore, novel therapies are badly needed for this 
type of cancer. 
 
1.2 Tumor initiating cells (TICs)/cancer stem cell (CSCs)  
 
TICs/CSCs are hypothesized to be derived from a small population of stem cells 
or early progenitor cells in tumor tissue, and are capable of self-renewal and 
differentiation as well as tumorigenesis, metastasis and drug resistance [9].  This special 
population of cancer cells is thought to be responsible for the origin and maintenance of 
tumors. The first evidence to support the TIC concept came from the human leukemia 
studies by Bonnet and Dick [10]. They isolated a specific small population of cells from 
acute myeloid leukaemia (AML) patients and showed that this population could initiate 
AML following injection into non-obese diabetic mice with severe combined 
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immunodeficiency (NOD/SCID). M.S. Wicha and co-workers isolated a population of 
cells using fluorescence-activated cell sorting (FACS) based on the phenotype epithelial 
surface antigen (ESA+)/ Cluster of Differentiation 44 (CD44+)/ Cluster of Differentiation 
24 (CD24-) from primary human breast tumors and found that less than 200 cells formed 
tumors 100% of the time when injected into NOD/SCID mice; whereas, 10,000 unsorted 
cells achieved 25%  tumor take [11]. These studies support the concept that a small 
population of tumor cells (TICs/CSCs) is responsible for development, maintenance and 
differentiation into heterogeneous "bulk" tumor cells in several cancer types, including 
breast cancer.  
Although chemotherapy and radiotherapy reduce breast tumor bulk (non-TIC), the 
majority of patients receiving such treatments develop tumor relapse or distant metastatic 
tumors [12]. Local tumor relapse and distant metastases following treatment are thought 
to be associated with breast TICs that are resistant to these treatments. TICs have two 
important features that contribute to tumor progression: First, TICs have acquired EMT 
for enhanced metastatic capacity, and second they are resistant to chemotherapeutic drugs 
and radiation therapy. Accumulating evidence supports the notion that both 
chemotherapy and radiotherapy only kill bulk cancer cells (non-TICs), thereby enriching 
TICs [9], thus, potentially promoting tumor recurrence, drug resistance and metastasis. 






 staining, were reported to increase 30 
fold following treatment with Taxol or 5-flurouracil in vitro using human breast cancer 
cell lines (SUM 159 and MDA-MB-231 cells) [13]. In addition, Ginestier and co-workers 
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reported that docetaxel treatment increased the number of ALDH+ population, an 
established TIC marker, in xenograft mouse models of human breast cancer when 
compared to control mice [14]. Such data may explain, at least partially, how chemo-
resistance or radio-resistance is developed [16]. Since many cancer therapies target only 
non-TICs that make up the bulk of a tumor, tragically the outcome of treatments is tumor 
relapse [9]. Thus, development of anticancer agents that can target both non-TICs and 
TICs provide promise of being an effective strategy for prevention and treatment of 
breast tumors.  
      Rapid advances in our understanding of TICs, including development of 
technologies for identifying TICs, are currently being made. The method of serial 
transplantation of a small number of sorted TIC-enriched human breast tumor cells to 
form tumors in NOD/SCID mice serves as an in vivo "gold standard" for showing the 
presence of TICs. Although there are no universal cell surface markers for the 
identification of TICs, which is a major limitation for TIC studies, several breast TIC 


















been used by Al-Hajj et al. and others to identify TICs from primary breast tumors and 
human breast cancer cell lines [15, 16 and 17]. Increased ALDH
+
 has been associated 
with TICs in breast as well as other cancer types [14].  ALDH positive activity was 
shown to be expressed in 577 human breast carcinomas and to serve as a stem/progenitor 
cell marker in vitro and in vivo in certain breast cancer cell lines including SUM 159, 
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population has been found to have TIC properties in MDA-MB-231 breast cancer cells 
[19]. The unique feature of TICs grown in non-differentiation media to form tumor 
spheres provides an in vitro mammosphere formation assay for identification of breast 
TICs. Cells isolated from mammospheres were shown to be more stem-like based on 
their epithelial-like morphology and expression of marker cytokeratin14 (CK14) which is 
associated with myoepithelial cells, and expression of cytokeratin18 (CK18), a marker 
for luminal cells when grown in differentiating conditions but not expressed in non-
differentiating conditions [15].  TICs isolated from mammospheres also have been 
shown to express the self-renewal undifferentiated stem cell marker octamer-binding 
transcription factor 4 (Oct-4), and to generate tumors when as few as 1,000 cells were 
transplanted into the mammary fat pad of SCID mice [15]. Data reported in this 
dissertation used an ALDH activity assay and standard in vitro serial mammosphere 
assays for identifying TIC populations in human breast SUM 159 and MDA-MB-231 
TNBCs.  
      A better understanding of molecular signaling pathways that regulate TIC 
survival, renewal and differentiation is necessary for the development of targeted therapy 
to eliminate TICs. Wnt/-catenin, Notch, Hedgehog, Her-2/PI3K/AKT, 
PI3K/mTOR/Stat-3 and PTEN/Akt have been identified as regulators of TIC self-renewal 
[20, 21, 22 and 23]. Therefore, identification of agents that target one or more of these 
pathways provides potential for development of novel strategies for eliminating TICs.  
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      Signal transducers and activators of transcription 3 (Stat-3) is a transcription 
factor [24] involved in cell proliferation, metastasis, and cell survival [25]. In response to 
cytokines and growth factors, Stat-3 family members are phosphorylated by receptor-
associated kinases followed by formation of homo- or heterodimers that translocate to the 
cell nucleus, where they function as  transcription activators or repressors [24]. Reports 
show that 50% of breast cancers express phosphorylated Stat-3 (pStat-3), with basal-like 
breast cancer cells expressing even higher levels [26, 27]. pStat-3 has been shown to be 




 populations, to be necessary for tumor cell 
proliferation [27], and to be involved in maintaining TICs in breast cancer cell 
populations, including SUM 159 cells [27, 28 and 29]. Thus, promising in vitro and in 
vivo data point to Stat-3 signaling as a potential target for TIC elimination in basal-like 
breast cancer, including TNBC. In this study, for the first time, we demonstrated that 
DHA and DHA + T3 possess the ability to eliminate TICs and to suppress Stat-3 
signaling.  
1.3 The anticancer actions of natural active compounds, vitamin E and 
docosahexaenoic acid 
 
      Accumulating evidence supports the notion that certain natural compounds 
possess anticancer activity via targeting both bulk tumor cells and TICs. Food derived 
compounds that have been identified to possess the ability to target TICs include 
curcumin, a natural compound extracted from curry and piperine from black and long 
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peppers singly and in combination. Curcumin and piperine have been shown to inhibit 
TIC self-renewal [30].  Several other natural compounds also have been shown to 
possess in vitro and/or in vivo anti-TIC properties including sulforaphane and piperine 
[31], galiellalactone [32], sesquiterpene lactone parthenolide [33], soy isoflavone 
genistein [34, 35], blueberry [35], T3 [36] and DHA [37]. Since most food-derived 
compounds show no or low toxicity these compounds possess great potential as 
anticancer agents for cancer prevention and treatment. Studies described in this 
dissertation are focused on two of these natural source dietary compounds, vitamin E and 
DHA.      
  
1.3.1 Vitamin E 
 
1.3.1.1 Structures and sources of Vitamin E 
 
      Vitamin E is a general term used indiscriminately to refer to a group of eight 
different naturally occurring compounds known as tocopherols and tocotrienols, as well 
as synthetic vitamin E (all-rac--tocopherol) and analogs of vitamin E  such as 
(α‐TEA/2,5,7,8‐tetramethyl‐2R‐(4′R,8′R,12′‐trimethyltridecyl) chroman‐6‐yloxy acetic 
acid and RRR‐α‐tocopheryl succinate/vitamin E succinate (VES)/α‐TOS] [38]. Vitamin E 
is a family of fat soluble compounds consisting of a functional phenolic group on a 
chroman head and an attached phytyl tail [38]. There are eight naturally occurring 
vitamin Es, which are divided into two categories based on the degree of saturation in the 
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phytyl tail; tocopherols or tocotrienols. Both tocopherols and tocotrienols can be further 
divided into four forms ( or based on the numbers and location of methyl groups 
on the chroman head[38] (Fig 1.1). All tocopherols and tocotrienols found naturally in 
foods exhibit 2R stereochemistry. Among them, RRR--tocopherol (T) is considered 
the most biologically active form since it is retained in human tissues at the highest 




Fig 1.1 Structures of various forms of tocopherols and tocotrienols of Vitamin E. 
Tocopherols and tocotrienols differ due to their saturated or unsaturated phytyl tails, 
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respectively. Based on the numbers and location of the methyl group on the chroman 
head, they are named  and forms (adapted from [39]). 
 
Different naturally occurring vitamin E forms are present in some plants [38]. 
Plant products such as nuts and soybean oils are enriched for tocopherols and palm oil, 
cereal grains, wheat germ and rice bran are enriched for tocotrienols [38]. Both RRR--
tocopherol and all-rac--tocopherol can be purchased as acetate or succinate derivatives 
and are used as FDA approved vitamin E supplements and food additives [38]. Recently, 
gamma-tocotrienol enriched fraction extracted from rice bran and palm oil, and delta-
tocotrienol enriched fraction extracted from annatto beans became available 
commercially [40].  
 
1.3.1.2 Digestion, absorption and metabolism of Vitamin E 
 
      Tocopherols are absorbed directly from the diet; however tocotrienols are usually 
esterified and have to be hydrolyzed before absorption [41]. Similarly, synthetic ester 
forms of tocopherol have to be hydrolyzed before absorption. Pancreatic and duodenal 
mucosal esterases participate in hydrolyzation of ester forms of tocopherols and 
tocotrienols for absorption [41]. 
All vitamin E forms are thought to be absorbed equally in micelles along with the 
absorption of other fat soluble products [41]. Next, the various vitamin E forms are 
incorporated into chylomicrons which are the major lipoproteins for transporting 
exogenous fat to cells and tissues via the circulatory system [42].Vitamin E remaining in 
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the chylomicrons remanents are incorporated into the liver for re-packaging into very low 
density lipoproteins (VLDL) and then secreted back into circulation [42]. A specific 
protein in the liver called alpha-tocopherol transfer protein (-TTP) is necessary for the 
selective transfer of RRR--tocopherol into VLDLs [43]. Because of the high selectivity 
of -TTP for RRR--tocopherol, other vitamin E forms are poorly secreted back into the 
circulation [41]. Although T is the predominant form of vitamin E in the American diet, 
RRR--tocopherol is the dominant form of vitamin E in the body. 
Elimination of excess vitamin E involves -hydroxylation of the phytyl side chain, 
followed by several -oxidations. Cytochrome P450 (CYP450) enzymes especially 
CYP4F2 and CYP3A4 catalyze -oxidation. Oxidation of the side chain results in the 
formation of carboxyethyl-hydroxychromane (CEHC) which may be conjugated with 
glucuronic acid and eventually excreted in the urine [44]. Both tocotrienols and 
tocopherols have been shown to activate a reporter gene driven by pregnane-X-receptor 
(PXR), a member of the family of nuclear receptors [45]. CYPs are induced by the 
activation of PXR [45]. Therefore, vitamin E can activate CYPs via activation of PXR, 
leading to elimination of vitamin E. The metabolism of vitamin E is tightly controlled. 
 
1.3.1.3 Functions of natural forms of Vitamin E 
 
       Vitamin E was first discovered in 1922 by H. Evans and K. Bishop as a 
micronutrient to maintain reproduction in rats [46]. Following the initial finding, many 
11 
 
studies focused on the benefits of vitamin E leading to the discovery of eight vitamin E 
isomers. Vitamin E is best known as an antioxidant [38]. The antioxidant property of 
vitamin E results from the ability to donate hydrogen ions to free radicals from the 
hydroxyl group on the phenolic ring of vitamin E [41]. Most of the vitamin E antioxidant 
investigations have focused on T, the major form in the body [47].  Supplementation 
with natural (RRR-T) or synthetic (all-rac-T) vitamin E has been associated with  
reductions in risk of chronic diseases like cardiovascular disorders [48], atherosclerosis 
and neurodegenerative diseases [49]. Besides these antioxidants properties, vitamin E’s 
anti-cancer activities have provided mixed results [38]. Although many efforts have been 
made to prove the chemo-preventive role for natural or synthetic vitamin E in cancer, no 
evidence has been provided to support a beneficial effect of T, T derivative (R,R,R--
tocopheryl acetate) or synthetic vitamin E acetate derivative (all-rac--tocopheryl 
acetate) on human cancer prevention [38]. A randomized, placebo-controlled trial 
(Selenium and Vitamin E Cancer Prevention Trial [SELECT]) on prostate cancer 
conducted between 2001 and 2004 did not find any benefit of all-rac--tocopheryl 
acetate for cancer prevention. In this study 35,533 men from 427 participating sites in the 
United States, Canada, and Puerto Rico were tested for the effect of selenium (200 μg/d 
from L-selenomethionine), vitamin E (400 IU/d of all-rac--tocopheryl acetate) and 
combination of selenium and vitamin E for prevention of prostate cancer [50]. Recent 
SELECT follow-up studies showed higher prostate cancer incidence in subjects who 
were given all-rac--tocopheryl acetate supplementation [51]. However, accumulating 
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data suggest that other forms of vitamin E such as gamma- and delta-tocopherols and -
tocotrienols possess anticancer activities against breast cancer [52], prostate cancer [53], 
skin cancer [54] and hepatocarcinogenesis [55]. 
 
1.3.1.4 Anticancer activities of tocopherols and tocotrienols 
 
       With the disappointment of the findings in SELECT, studies have focused on the 
anticancer properties of other forms of vitamin E. Several in vitro and in vivo studies 
show that both gamma- and delta-tocopherols and -tocotrienols possess anticancer actions 
[56, 57 and58].   
        γT is the most common vitamin E form in the American diet and is found 
enriched in soybean and corn oils [57]. T is primarily found in soybean and castor oils 
[57].  Studies show that γ and δT induce apoptosis in a variety of cancer cells including 
breast, colon and prostate cancer [57]. Both tocopherols have been shown to inhibit 
tumor growth in a lung xenograft model, but αT did not [59]. In vitro studies showed that 
δT was more effective than γT in inhibiting cell growth, whereas αT was not effective 
[60]. Several mechanisms have been proposed to account for the anti-cancer activities of 
tocopherols. One study showed that tocopherols arrest the cell cycle at the S phase as 
well as suppressed cyclin D1 and cyclin E protein levels [61]. Tocopherols also have 
been shown to induce apoptosis, involving activation of caspases-9 and -3, as well as 
interruption of the synthesis of sphingolipids [57]. γT or the combination of γT plus δT 
have been shown to induce apoptosis by induction of cytochrome c release, activation of 
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caspases-9 and -3, and cleavage of Poly (ADP-ribose) polymerase (PARP) in human 
prostate LNCaP cells. A study from our lab showed that γT induces human breast cancer 
cells to undergo apoptosis via DR5 pathway [62]. 
       Tocotrienols exhibit antitumor actions in vitro, including induction of apoptosis 
[52], inhibition of cell proliferation and inhibition of angiogenesis [63]. Furthermore, T3 
has been shown to possess anticancer actions in preclinical animal models [52], and  
reported to inhibit NF-kB,  a transcription factor regulating anti-apoptotic, inflammatory 
and angiogenic factors [64]. Ahn, et al. reported that T3 downregulates NF-kB in 
pancreatic cancer cells as well as down-stream anti-survival factors [B-cell lymphoma-
extra large (Bcl-xL), B-cell lymphoma 2 (Bcl-2), Cellular caspase-8 (FLICE)-like 
inhibitory protein (cFLIP), X-linked inhibitor of apoptosis protein (XIAP) and survivin, 
anti-proliferation factors (cyclin D, cMyc), and anti-angiogenesis factors-Vascular 
endothelial growth factor (VEGF) [65]. Shah et al. showed that T3 suppressed the 
PI3K/AKT survival signaling pathway in malignant mouse mammary cells [ 66 ]. 
Moreover, suppressed PI3K/AKT was associated with inactivation of anti-apoptotic 
factor c-Flip and activation of pro-apoptotic factor caspase 8 [66]. Our lab has reported 
that T3 induces apoptosis in MCF-7 and MDA-MB-231 human breast cancer cells in 
vitro via activation of a c-Jun N-terminal kinases (JNK)/ CCAAT-enhancer-binding 
protein homologous protein (CHOP)/DR5 pro-apoptotic pathway and suppression of c-
FLIP and Survivin anti-apoptotic factors, and inhibits tumor growth in a transplantable 
syngeneic BALB/c mouse 66cl-4-GFP mammary cancer model [52].  A recent in vivo 
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and in vitro study firstly reported that T3 targets prostate TICs [67]. It has also been 
reported that T3 and T3 levels specifically accumulated in tumor tissue although they 
were not detected in liver and lung, further supporting the application potential of 
tocotrienols for cancer prevention and treatment [68]. A recent pilot clinical trial has been 
conducted to test the effect of the combination of tocotrienol rich fraction with tamoxifen 
in women with early diagnosed breast cancer. Although the study did not achieve a 
statistically significant benefit in a 5 year survival rate, there was a positive trend in that 
the combination of tocotrienol rich fraction plus tamoxifen had higher survival rates [69]. 
A recent phase I clinical trial has been initiated to study the effects of T3 on pancreatic 
cancer patients [70]. This study will be the first study to test different doses of a single 
tocotrienol in patients [71]. It has been reported from this study that a dosage of 800 
mg/day were well tolerated by patients. Accumulated promising data suggest that T3 
may be an effective anti-cancer agent alone as well as with other anticancer agent to 
enhance its anticancer effects and reduce toxicity [71].  
1.3.2 Docosahexaenoic acid (DHA)  
 
         DHA is a long-chain (22 carbon) omega-3 highly unsaturated fatty acid (n-3 
HUFA). It has six cis double bonds with the first double bond located at the third carbon 
from the omega (methyl) end [72]. DHA is highly enriched in cold water fishes such as 
salmon, herring, mackerel and sardines and their oils are widely used as dietary 
supplements [73].  
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1.3.2.1 Synthesis and metabolism of polyunsaturated fatty acids (PUFAs) 
 
          PUFAs can be divided into different families based on the location of the 
first double bond from the methyl end.  They are n-3 and n-6 families. Linoleic acid 
(LA; 18:2 n-6) and  α-linolenic acid (ALA; 18:3 n-3) are precursors of n-6 and n-3 
highly unsaturated fatty acids (HUFAs) containing more than 20 carbons, respectively 
[74]. Linoleic and linolenic fatty acids are essential for humans since humans do not 
possess enzymes capable of inserting double bonds at the omega-3 and 6 positions [74]. 
Both linoleic and -linolenic fatty acids can be metabolized to 20 or 22-carbon long-
chain fatty acids by delta-4,5,6 desaturases and elongases [75]. LA is metabolized to 
arachidonic acid (AA; 20:4 n-6), and ALA to eicosapentaenoic acid (EPA 20:5 n-3) and 
DHA (22:6 n-3) (Fig 1.2) [75]. The efficiency of conversion from ALA to EPA and DHA 
is small and variable [76]. It has been shown that 8% to 20% of ALA is converted to EPA 
in humans and only 0.5% to 9% of ALA is converted to DHA [76].  Burgee and co- 
workers compared the apparent conversion efficiency of ALA to DHA in men and 
women. There was no detectable conversion found in men whereas an efficiency of 9% 
was observed in women [77]. Therefore, the conversion of ALA to DHA is limited and 





Fig 1.2 metabolism of omega-3 and omega-6 PUFAs  Metabolisms of PUFAs begins 
from their precursors ALA n-3 and LA n-6 found in diets. ALA is metabolized by 
Δ6desaturation, elongation and Δ5 desaturation, further elongation and Δ6 desaturation 
and beta oxidation in peroxisomes and resulting in the production of DHA. With the 
participation of same enzymes in the conversion of ALA to EPA and DHA, LA is 
converted to docosapentaenoic acid (DPA). (adapted from [75]). 
 
Among these two families, n-3 and n-6 are competing for the desaturation enzymes. 
Although both Δ-5 and Δ-6 desaturases prefer omega-3 to omega-6 fatty acids, a high LA 
intake interferes with the desaturation and elongation of ALA to n-3 FAs [75]. These two 
categories of HUFAs have important opposing physiological functions because of 
different oxidized metabolites; namely different eicosanoid products produced by n-3 and 
n-6 FAs. AA and DHA or EPA are parent compounds of eicosanoids (Fig 1.3). Both AA 
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and DHA/EPA are metabolized by cyclooxygenases (COX) and lipoxygenases (LOX) 
enzymes. AA serves as a substrate of COX to produce pro-inflammatory products like 
prostaglandins (PGE2), prostacyclins (PGI2) and thromboxanes (TXA2) [78]. AA also 
can be oxidized by LOX for the production of   Leukotriene E4 (LTE4). Generally, 
eicosanoids produced from AA are more pro-inflammatory [78].  DHA/EPA produce 
eicosanoids such as prostaglandin 3 (PGE3), resolvins, leukotriene 5 (LTE5) and 
protection Ds which have less pro-inflammatory or anti-inflammatory effects (Fig 1.3) 
[79]. Cell culture and animal studies have shown that n-3 PUFAs are protective; whereas, 
n-6 PUFAs promote inflammation and cancer [80]. It is hypothesized that a very high 
omega-6/omega-3 ratio, as is found in today’s Western diets, promotes the pathogenesis 
of many diseases, including cardiovascular disease, cancer, and inflammatory and 
autoimmune diseases [80]. Thus, the ratio of dietary n-6/n-3 taken is very important for 
human health, with a  recommendation that the ratio of n-6/n-3 is close to 1 [75]. 
However, studies [75] show that the ratio of n-6/n-3 is 15/1–16.7/1 in Western diets. This 
review of omega-3 and omega-6 highlights an urgent need for Americans as well as 
people in many other countries to address the lop-sided n-3/ n-6 ratio. Studies in this 
dissertation focus on the anticancer beneficial effects of n-3 DHA alone and in 





Fig 1.3 Oxidized metabolism of n-3 and n-6 PUFAs to produce their respective 
eicosinoids and pro-resolving products Eicosanoids such as LTE4, 5-HETE, PGI2, 
PGE2 produced from AA are more pro-inflammatory. PGI3, PGE3, LTE5 produced from 
DHA/EPA are less inflammatory and resolving, E1 is anti-inflammatory. (Adapted from 
[74]). 
 
 1.3.2.2 Anticancer functions of DHA 
The health benefits from the consumption of n-3 HUFAs are evident in the 
Greenland Eskimos [81]. They consume a high seafood diet rich in n-3 and have low 
rates of coronary heart disease, asthma and diabetes mellitus. Furthermore, there is 
sufficient data to show that the n-3 FAs provide benefits in prevention of cancer, 
inflammatory disease, immune system disease and psoriasis. However, too much DHA 
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intake could cause side effects such as nausea, gas or prolonged bleeding . The incidence 
of hemorrhagic stroke is higher among Greenland Eskimos [82]. It has been documented 
that n-3 PUFAs can reduce platelet aggregation, inhibiting blood clotting [83].  A study  
by Yongsoon Park et al. showed that intake of DHA+EPA increase the risk of 
hemorrhagic stroke in a rat model [84].                 
The anti-inflammation and cardioprotection functions of DHA have been well 
documented [85, 86]. Accumulating data from cell culture, animal studies and human 
clinical trials suggest that DHA can reduce tumorigenesis in a variety of cancers, 
including breast cancer [87]. The effects of DHA on inhibition of proliferation, metastasis 
and angiogenesis, as well as induction of apoptosis in MDA-MB-231 cells have been 
reported [88].  In vitro data show DHA to induce apoptosis and inhibit metastasis via 
multiple mechanisms, including inhibition of biosynthesis of proinflammatory molecules 
such as COX-2 [89], activation of PPAR-[89], suppression of NF-kB [90], generation 
of reactive oxygen species (ROS) [91], and ER-stress [92]. n-3 PUFA’s are readily 
incorporated into the lipid micro-domains of cellular membranes, which may enhance 
membrane-associated signaling proteins such as Ras, Akt, EGFR and lipids such as 
ceramide [93, 94]. Recently, Kent et al. reported that DHA significantly inhibited 
secondary mammosphere formation in cells isolated from polyoma virus middle T virus 
spontaneous mammary cancer mouse model [95], an in vitro method for testing self-
renewal of TICs [96] and induces apoptosis of TIC-enriched colon cancer cells [37], 
suggesting the potential of DHA to eliminate TICs. Taken together, data suggest that 
20 
 
DHA is a promising nutrient-based anticancer agent to prevent metastasis and tumor 
recurrence, or eradicate cancers since DHA possesses the potential to target both TICs 
and non-TICs.   
1.4. Apoptosis and Endoplasmic Reticulum stress (ER stress) 
1.4.1 Introduction of Apoptosis and ER stress 
 
    Apoptosis is one form of programmed cell death (PCD) [97]. It is characterized by 
cell morphology changes including blebbing, shrinkage, nuclear fragmentation, 
chromatin condensation, and chromosomal DNA fragmentation. In contrast to apoptosis, 
necrosis is a nonspecific form of cell death, characterized by rupture of the plasma 
membrane with inflammatory responses and damage to surrounding cells and tissues 
[98]. Apoptosis often provides beneficial effects to the organism, while necrosis is almost 
always detrimental and can be fatal [ 99 ] due to the inflammatory responses to 
surrounding cells and tissues. Apoptotic cells are engulfed and removed by phagocytic 
cells when they receive the “eat-me” signals from the apoptotic cells [98]. This 
characteristic of apoptosis provides the opportunity for clinical use to selectively target 
tumor cells but not damage normal cells.  
      Two major signaling pathways are involved in triggering apoptosis, the extrinsic 
pathway (death receptor pathway) and intrinsic pathway (mitochondrial pathway) [100] 
(Fig 1.4). Cysteine-aspartic proteases (caspases) are a family of cysteine proteases that 
play essential roles in apoptosis [101]. Caspases are divided into two categories: Initiator 
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caspases such as caspases 2, 8, 9 and 10 which act in cleaving inactive pro-forms of 
effector caspases to activate them, and effector caspases, also named executioner 
caspases such as caspases 3, 6 and 7, which function in cleavage and activation of their 
protein substrates to trigger apoptosis processes [101].  
Intrinsic stresses, such as oncogene dysregulation, direct DNA damage, hypoxia, 
and survival factor deprivation, can activate the intrinsic apoptotic pathway [100] (Fig 
1.4). The intrinsic pathway is characterized by changes in the mitochondria membrane 
permeability and release of two main groups of pro-apoptotic proteins [102]. One group 
of the pro-apoptotic proteins includes cytochrome c and Smac/DIABLO in group 2 [103]. 
Cytochrome c forms an apoptosome via binding of Apaf-1 and procaspase-9 [104]. This 
binding results in the activation of caspase-9 and caspase-3. Smac/DIABLO induce 
apoptosis via inhibiting IAP (inhibitors of apoptosis proteins) activity. The other group of 
pro-apoptotic proteins includes Apoptosis inducing factor (AIF), endonuclease G and 
Caspase-Activated DNase (CAD). AIF causes DNA fragmentation [ 105 ] and 
endonuclease G cleaves nuclear chromatin to cause DNA fragmentation [106]. AIF and 
endonuclease G both function in a caspase-independent manner, whereas CAD induces 
apoptosis via activation of caspase-3 [107]. Bcl-2 family proteins control and regulate 
mitochondrial dependent apoptotic events [108]. These proteins can be divided into pro-
survival and anti-apoptotic proteins. Bcl-2, Bcl-x, Bcl-XL, Bcl-XS, Bcl-w, BAG function 
as anti-apoptotic (pro-survival) proteins, while Bcl-10, Bax, Bak, Bid, Bad, Bim, Bik, and 
Blk function as pro-apoptotic (death) proteins [100]. The balance of these anti- and pro-
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apoptotic Bcl-2 proteins decides the fate of cells; death or survival.  The main action of 
Bcl-2 family members in controlling apoptosis is to regulate cytochrome c release from 
the mitochondria. The extrinsic and intrinsic pathways cross-talk [100]. In both cases, if a 
cell is initiated by either pathway, the mitochondria membranes become permeable to 
release cytochrome c to form apoptosome to activate executioner caspase 3 [101]. 
 
 
Fig 1.4 extrinsic and intrinsic pathways of apoptosis extrinsic pathway starts by 
activating death receptors on cell membranes. Adaptor proteins initiate DISC which 
activates caspase 8 and then caspase 3 to trigger apoptosis. The intrinsic pathway is 
characterized by changes in the mitochondria membrane permeability and release of two 
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main groups of pro-apoptotic proteins-Cytochrome c, Smac/DIABLO, and endonuclease 
G. Smac/DIABLO and Endo G induce apoptosis via inhibiting IAPs activities. Released 
cytochrome c form apoptosome to activate executioner caspase 3 to trigger 
apoptosis.(adapted from [109])  
 
 
The extrinsic apoptotic pathway is initiated by activation of death receptors via 
their ligands such as Fas receptor and Fas ligand, and death receptor 4/5 (DR4/DR5) and 
their TNF-related apoptosis-inducing ligand (TRAIL). Once the cell receives the death 
stimuli, death receptors and their ligand complexes recruit death-containing protein 
(FADD) and caspase-8 to form the death-inducing signal complex (DISC) [100], leading 
to cleavage and activation of caspase-8. Activation of caspase-8 can be blocked by 
FLICE inhibitory protein (FLIP) via competition with caspase-8. Caspase 8 triggers 
apoptosis via activation of effector caspase, caspase-3.  
Triggering cells to undergo stress is another mechanism to induce apoptosis, such 
as oxidative stress and ER stress. ER is the organelle which is responsible for synthesis 
and folding of proteins, synthesis of steroids, cholesterol and some other lipids [110], and  
also a calcium storage and signaling site. ER functions in an oxidative environment with 
chaperone proteins and high levels of calcium. All secretary proteins enter the ER before 
they enter the Golgi complex where they undergo post-translational modifications and 
folding to form disulfide bonds [111]. Correctly folded proteins are transported out of the 
ER and down to their secretory pathways; whereas, misfolded proteins are degraded by 
cytoplasmic proteasomes. Disruption of any of these processes causes ER stress [111]. 
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ER stress is associated with activation of specific signaling pathways including the 
unfolded protein response (UPR) and some diseases including cancer [112]. In the lumen 
of the ER, chaperone glucose regulated protein (GRP78) (also named BIP) expression is 
increased in a variety of cancers including breast, lung and colon cancers [113]. In cells 
under non-stressed condition, GRP78 binds to transmembrane sensor proteins such as 
pancreatic ER kinase-like ER kinase (PERK), inositol-requiring enzyme 1 (IRE1), and 
activating transcription factor 6 (ATF6) where they remain in an inactive form [114] (Fig 
1.5). Whereas, cells under stress accumulate unfolded proteins and GRP78 pulls away 
from the unfolded proteins and these sensor proteins are released and activated, leading to 
UPR [114]. UPR is involved in restoring or repairing the normal functions of ER via 
activation of signaling pathways to produce factors involved in folding proteins. If ER 
stress damage cannot be repaired within a certain period of time, UPR is involved in the 
initiation of apoptosis. 
       IRE1 oligomerizes in ER membranes when released by GRP78. It contains a Ser/Thr 
kinase domain and an endoribonuclease domain. The endoribonuclease domain processes X 
box protein-1 (XBP-1) mRNA [116]. IRE1 plays a key role in the removal of an intron 
from XBP-1, leading to the production of XBP-1 protein, a transcription factor that 
regulates several genes involved in the degrading and transport of misfolded proteins to 
the cytosol [116]. The Ser/Thr kinase domain of IRE1 is self-activated and 
autophosphorylated upon release from GRP78 [116]. IRE1 then binds to receptor-
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associated factor-2 (TRAF2) and apoptosis-signal-regulating kinase 1(ASK1). ASK1 
activates cell death signaling pathways via JNK [116]. 
PERK is a Ser/Thr protein kinase. Once detached from the GRP 78 complex, it is 
activated via autophosphorylation. It phosphorylates and inactivates the eukaryotic 
initiation factor 2α (eIF2α) family and thereby shuts off mRNA translation and reduces 
the protein load on the ER [116]. Certain genes gain advantage for translation from 
inactivation of eIF2a like activating transcription factor 4 (ATF4). ATF4 is a member of 
the bZIP family of transcription factors which regulates several genes involved in the 
UPR [116]. Release of GRP78 also releases ATF6 which translocates to the golgi 
apparatus where it is cleaved by resident proteases at a juxtamembrane site, thereby, 
releasing it into the cytosol where it is to transferred to the nucleus where it is involved in 
the  regulation of  gene expression, including genes like XBP1 and GRP78 which are 
involved in ER homeostasis [116].  
1.4.2 C/EBP homologous protein (CHOP)/Gadd153, an ER stress-induced cell death 
modulator  
 
CHOP is also called growth arrest and DNA damage-inducible gene 153. It is a 
member of the C/EBP family of transcription factors which is involved in ER stress-
mediated apoptosis [52].  CHOP is regulated by XBP1, ATF6 and ATF4 that bind to 
cis-acting elements in the promoter region [116] (Fig 1.5). Several reports have shown 
that CHOP negatively regulates cell growth and promotes ER stress-induced apoptosis 
[115]. CHOP is constitutively expressed at low levels in cells, but increases when cells 
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are under ER stress [116]. Several studies have investigated the role of overexpression of 
CHOP in ER stress induced apoptosis [117,118]. Reduced apoptosis under ER stress was 
observed in chop-/- mice [119]. Targeted genes that are regulated by CHOP includes 
GADD34 and Bcl-2 family members such as anti-apoptotic Bcl-2 and pro-apoptotic Bim, 
Bak and Bax, as well as DR5.  
 
Fig 1.5 Mechanisms involved in regulation of ER stress mediators. PERK, ATF6 and 
IRE1 are released from chaperones upon UPR. followed by activation of a series of 
events resulting in activation of CHOP.  CHOP, a transcription factor, regulates 




1.5 Specific Aims and Objectives 
 
         Breast cancer is the most frequently diagnosed cancer in women in the United 
States.  Triple negative breast cancer (TNBC), which constitutes the majority of the 
basal-like subtype of breast cancer, represents 15-20 % of breast cancers in women.   
Due to lack of both estrogen and progestrone receptors as well as epidermal growth factor 
recetor-2 (HER-2), the only available treatment for TNBC is chemotherapeutics. 
Although TNBC patients are initially sensitive to chemotherapeutics, recurrent tumors 
often occur, which are associated with multi-drug resistance and metastasis.  Patients 
with TNBC have a poor prognosis and low 5 year survival rate. Due to the lack of 
effective therapeutics for TNBCs, there is a great need for development of new 
therapeutics with low to no toxicity that eliminate breast tumors, especially TNBC 
tumors. Can dietary nutrients serve as  therapeutics for certain cancers? Accumulating 
data show that certain natural compounds, separately and in combination, possess 
anticancer activity via targeting both bulk tumor cells as well as TICs, also referred to as 
CSCs. Since most natural compounds exhibit no or low toxicity, these compounds 
possess great potential as anticancer agents for cancer prevention and treatment.  
Objective: 
 Investigate the ability of two low to no toxic nutrients, DHA and T3, alone and 
in combination, to eliminate both human TNBC breast bulk cancer cells and TICs in 
culture.  DHA, a long-chain (22 carbon) omega-3 poly unsaturated fatty acid enriched in 
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cold water fishes, has been reported to have the ability to reduce tumorigenesis in a 
variety of cancers including breast cancer. Vitamin E describes a family of eight 
compounds, four tocopherols and four tocotrienols found primarily in vegetable oils, 
seeds and nuts. T3 has been shown to target several cancers, including breast cancer as 
well as prostate TICs in vitro and in animal models.  
Specific Aims:  
1) Identify the distinct roles of different forms of vitamin E in combination with 
DHA in TNBCs in vitro, and establish an understanding of the underlying mechanisms of 
action. 
2) Determine the ability of DHA alone and in combination with T3 to eliminate 
TNBC TICs, and examine mechanisms of action.  
  3) Evaluate the anti-tumor actions of - and (delta ) tocopherols, - and -
tocotrienols in induction of apoptosis in bulk TNBCs and for elimination of TICs;  and 
the absence of anti-tumor actions of natural vitamin E (RRR--tocopherol, T) and 
synthetic vitamin E  (all-rac--tocopherol).    
Dissertation Outline:  
Chapter 1 provides a review of the literature for establishing pertinent background 
information relevant to a better understanding of the anti-cancer actions of DHA and T3.  
Chapter 2 studies investigate the pro-apoptotic effects of DHA and mechanisms of action, 
including the involvement of reactive oxygen species and endoplasmic reticulum stress 
signaling pathways.  Furthermore, data highlight the distinct roles of two forms of 
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vitamin E, T and T3, in DHA-induced apoptotic events.  Chapter 3 documents DHA's 
ability to eliminate TICs in human TNBC and the cooperative effects of T3. Chapter 4 
addresses the anti-cancer actions of different forms of vitamin E in human breast cancer 
cell lines.  Chapter 5 summarizes the studies presented in this dissertation and proposes 
future research directions. 
 
Chapter 2  Distinct roles of different forms of vitamin E in DHA-  
 induced apoptosis in triple negative breast cancer cells  
2.1 Abstract  
Scope: DHA has been shown to exhibit anticancer actions in vitro and in vivo in a 
variety of cancers.  Here, we investigated the role for DHA in inducing apoptosis in 
TNBC and studied the mechanisms of action.  
Methods and results: DHA induces apoptosis as detected by Annexin V-FITC/PI 
assay; as well as, induces cleavage of caspase-8 and -9, ER stress and elevated levels of 
death receptor-5 (DR5) protein expression as detected by western blot assays. Chemical 
inhibitors of caspase-8 and -9, and small interfering RNAs (siRNAs) show DHA to 
induce ER stress/CHOP/DR5 mediated caspase-8 and -9 dependent apoptosis. 
Furthermore, DHA induces elevated cellular levels of ROS, and antioxidant T blocked 
DHA-induced apoptotic events. In contrast to the antagonistic impact of T, T3 was 
demonstrated to cooperate with DHA in inducing apoptotic events in TNBC cells.  
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Conclusion: Data, for the first time, demonstrate that DHA induces apoptosis in 
TNBC cells via activation of ER stress/CHOP/DR5 mediated caspase-8 and -9 dependent 
pro-apoptotic events, and that different forms of vitamin E exhibit distinct effects on 
DHA-induced apoptosis; namely, inhibition by T and enhancement by T3.   
2.2 Introduction  
 
TNBC is defined by a lack of expression of both estrogen and progesterone 
receptors; as well as, lack of human (Her-2) [6], and it has a poor prognosis due to lack of 
specific targeting therapy. TNBCs comprise 15-20% human breast cancer in Western 
countries [6]. The only therapeutic option currently available for TNBC is chemotherapy. 
However, prognosis for TNBC remains poor due to drug resistance and toxicity [7, 8]. 
DHA, a long-chain (22 carbon) polyunsaturated fatty acid (n-3 PUFA), is highly 
enriched in oils from cold water fishes (salmon, herring, mackerel and sardines) and 
widely used as a dietary supplement. DHA has a wide range of biological activities. Its 
anti-inflammation and cardioprotection functions have been well documented [85, 86]. 
Data from cell culture and animal studies, as well as human clinical trials suggest that 
DHA can reduce tumorigenesis and tumor development in a variety of cancers, including 
breast cancer [87]. DHA anticancer mechanisms include inhibition of proliferation, 
metastasis, and angiogenesis; as well as, induction of apoptosis [88]. In vitro data show 
DHA to induce apoptosis via multiple factors, including inhibition of biosynthesis of 
proinflammatory molecules such as COX-2 [89], activation of peroxisome proliferator-
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activated receptor (PPAR) [89], suppression of NF-kB [90], induction of ROS [91] and 
ER stress [92]. However, a complete understanding of the mechanisms whereby DHA 
induces apoptosis is not fully understood. Further insights into the signaling networks 
modulated by DHA may provide key insights into how DHA may be used for prevention 
and treatment of human breast cancer. 
Vitamin E is a general term used to refer to a group of eight naturally occurring 
compounds known as tocopherols (α, β, γ and δ) and tocotrienols (α, β, γ and δ) and 
synthetic vitamin E (all-rac--tocopherol); as well as, vitamin E analogs such as RRR--
tocopherol ether-linked acetic acid analogue (-TEA) [38]. Both RRR--tocopherol and 
all-rac--tocopherol can be purchased as acetate or succinate forms in traditional vitamin 
E supplements and as food additives to protect lipids from pro-oxidation. Tocotrienol 
forms of vitamin E are found in palm oil, cereal grains and rice bran [38]. To date, T3, 
T3 and Tocotrienol Rich Fraction (TRF) have been marketed as vitamin E supplements. 
Despite many research efforts, the anticancer functions of natural and synthetic vitamin E 
compounds remain to be clearly defined [38]. Pre-clinical studies suggest promise of a 
subset of vitamin E forms as anticancer agents; namely, gamma- and delta-forms of 
tocopherol and tocotrienol [56, 57 and 58]. However, there is no evidence that vitamin E 
supplements (T or all–rac-TAc) conferred any protection against breast cancer [38]. 
Instead, recent findings suggest that high dosage vitamin E supplements enhance the 
incidence of prostate cancer [50]. Thus, it is important to distinguish among the different 
vitamin E forms as to their anticancer actions.  
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In this study, we studied the mechanisms of DHA action on inducing apoptosis in 
TNBC and evaluated the effects of vitamin E compounds; T and T3, on DHA’s pro-
apoptotic actions. Data show that DHA induces apoptosis in TNBC cells via activation of 
ERS-mediated CHOP/DR5, and that T blocks and T3 enhances DHA pro-apoptotic 
actions. 
2.3 Materials and methods  
2.3.1 Cell Culture and Reagents 
MDA-MB-231, SUM159 and SUM149 human TNBC cell lines [121] were used 
in this study.  MDA-MB-231 cells were cultured in MEM media with 10% FBS as 
described previously [122]. SUM 159 and SUM 149 human breast cancer cells (Asterand, 
Inc. Detroit, MI) were cultured in Ham’s F12 medium (Invitrogen, Carlsbad, CA) with 
5% fetal bovine serum, 5 μg/ml insulin, 1μg/ml hydrocortisone (Sigma-Aldrich, St Louis, 
MO), and 10 mM HEPES buffer.  For experiments, FBS was reduced to 2% to all of 
media and cells were allowed to attach overnight before treatments. αT (TAMA 
Biochemical Company, LTD, Tokyo, Japan) and T3 (a gift from Malaysian Palm Oil 
Board, Kuala Lumpur, Malaysia) were dissolved in 1:4 DMSO/ethanol at 40 mM as 
stock solution. Equivalent levels of 1:4 DMSO/ethanol was used as vehicle control 
(VEH). N-acetyl cysteine (NAC, Sigma) was dissolved in H2O. 
Dichlorodihydrofluorescein diacetate (H2DCF-DA) was obtained from Invitrogen 
(Carlsbad, CA). Caspase 8 and 9 inhibitors: Z-IETD-FMK and Z-LEHD-FMK were 
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obtained from Biovision (San Francisco, CA). DHA was purchased from Sigma-Aldrich 
(St. Louis, MO). 
 
2.3.2 Western Blot Analyses  
Whole cell protein extracts were prepared and examined by western blotting as 
described previously [122]. Proteins at 15-30 g/lane were separated by SDS-PAGE and 
transferred to nitrocellulose (Optitran BA-S supported nitrocellulose, Schleicher and 
Schuell, Keene, NH). Antibodies to the following proteins were used: poly (ADP-ribose) 
polymerase (PARP), CHOP, and GRP-78 (Santa Cruz Biotechnology, Santa Cruz, CA), 
Caspase-8, Caspase-9, DR5, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
(Cell Signaling Technology, Beverly, MA). Horseradish peroxidase conjugated goat-anti-
rabbit or goat-anti-mouse secondary antibodies (Jackson ImmunoResearch Laboratories, 
Rockford, IL) were used and followed by detection with ECL PLUS solution kit 
(PerkinElmer, Waltham, MA).  
2.3.3 RT-PCR 
 
mRNA levels of spliced X-box binding protein 1 (XBP-1) was determined by RT-
PCR following a previously published protocol [123]. Briefly, total RNA was extracted 
using RNA isolation kit (Qiagen Inc. Valencia, CA). Semi-quantitative analyses were 
conducted to detect spliced XBP-1 mRNA form by reverse transcriptase-polymerase 
chain reaction (RT-PCR) using the housekeeping gene β-actin as a loading control. 4 µg 
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of total RNA was reverse transcribed to cDNA using 1 µl Superscript RTase (250 U, 
Invitrogen) following the manufacture's instructions. 1 µl cDNA was used per PCR 
reaction with 15 µl Taq PCR Master Mix Kit (Qiagen Inc) plus 10 µM oligonucleotide 
primer pairs (Invitrogen). 
2.3.4 RNA Interference  
 
A scrambled RNA duplex that does not target any of the known genes was used 
as the nonspecific negative control for RNAi (referred to as control siRNA). Transfection 
of MDA-MB-231 cells with siRNA to DR5 and   CHOP (Ambion, Austin, TX) were 
performed in 100 mm cell culture dishes at a density of 1.5×10
6
 cells/dish using 
Lipofectamine 2000 (Invitrogen) and siRNA duplex.  After one day exposure to 
transfection conditions, the cells were re-cultured in 100 mm dish at 1.5×10
6
 cells/dish 
and incubated for one day followed by treatments. 
2.3.5 Quantification of apoptosis  
 
Apoptosis was quantified by Annexin V-FITC/PI assays following the 
manufacturer’s instructions (Invitrogen, Carlsbad, CA) and published procedure [123]. 
The Annexin V-FITC/PI assay measures amount of phosphatidylserine on the outer 
surface of the plasma membrane (a biochemical alteration unique to membranes of 
apoptotic cells) and amount of propidium iodide (PI), a DNA binding dye that does not 
cross the plasma membrane of viable cells but readily enters dead cells or cells in the late 
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stages of apoptosis. Fluorescence was measured using FACS analyses with a FACS 
Fortessa flow cytometer (BD Bioscience). Cells displaying phosphatidylserine on their 
surface (positive for Annexin-V fluorescence) were considered to be apoptotic. Annexin 
V/FITC was a gift from Dr. Shawn Bratton (University of Texas at Austin).  
2.3.6 Detection of Reactive Oxygen Species (ROS)  
 
Intracellular ROS generation was detected by FACS analyses after staining the 
cells with H2DCF-DA, a cell-permeant ROS sensing probe for 30 minutes. H2DCF-DA is 
nonfluorescent until the acetate groups are removed by intracellular esterases and 
oxidation. Staining procedures followed the manufacturer’s instructions and Fluorescence 
was detected by a FACS Fortessa flow cytometer (BD Bioscience).  
 
2.3.7 Statistical Analyses 
 
Apoptosis data were analyzed using a one-way analysis of variance (ANOVA) 
followed by Turkey test for comparison of more than two treatments or a two-tailed 
student t-test for comparison between two treatments to determine statistical differences. 
Differences were considered statistical significant at p<0.05. 
2.4 Results 




DHA has been reported to induce apoptosis in estrogen receptor positive, PR+ 
and Her-2 low-expressed MCF-7 cells and estrogen receptor negative [124], PR- and 
Her-2 over-expressed SK-BR-3 [124] human breast cancer cells [125]. Here, we 
evaluated the effect of DHA on inducing apoptosis in TNBC cells. Treatment of cells 
with DHA at physiologically relevant concentrations [126] for 24 hrs induced apoptosis 
in a dose-dependent manner as detected by Annexin V/PI analyses (Fig 2.1A) and PARP 
cleavage, a biomarker for caspase dependent apoptosis (Fig 2.1B). It has been reported 
that DHA is incorporated into the cellular surface membrane within 5.2-17 minutes [127].  
Western blot analyses reveal that DHA induces cleavage of both caspase-8 and -9 (Fig 
2.1B). Caspase-8 (Z-IETD-FMK) and -9 (Z-LEHD-FMK) inhibitors significantly 
reduced DHA-induced apoptosis as detected by Annexin V/PI analyses (Fig 2.1C) 












Fig 2.1 DHA induces apoptosis in TNBC cells. TNBC cells were treated with DHA at 
different concentrations for 1 day followed by Annexin V/PI analyses to determine 
percentage of cells undergoing apoptosis (A) and western blot to determine protein levels 
of biomarkers of apoptosis; cleaved PARP (pre-PARP = full length PARP and cPARP= 
cleaved PARP) (B). TNBC cells pre-treated with Z-IETD-FMK (caspase-8 inhibitor) or 
Z-LEHD-FMK (casapse-9 inhibitor) for 3 hours followed by treatment of the cells with 
DHA at 60 M and 80 M for SUM 159 and MDA-MB-231 cells, respectively, for 1 day 
were analyzed for apoptosis using Annexin V/PI (C). Data in A and C are depicted as 
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mean + SD of three individual experiments. Data in B represents two separate 
experiments. * Statistically different from vehicle control (A) or DHA treatment alone 
(C), p<0.05.  
 
 
2.4.2 DHA induces ER stress.  
 
DHA has been reported to induce ER stress in human colon cancer cells [128]. To 
see if DHA induces ER stress in TNBC cells we determined the effect of DHA on the 
expression of ER stress biomarkers. Treatment of cells with increasing doses of DHA for 
1 day induced elevated levels of ER stress markers GRP78 and CHOP protein expression 
as detected by western blot analyses (Fig 2.2A), as well as, elevated levels of spliced 
XBP-1 mRNA expression as detected by RT-PCR (Fig 2.2B), indicating that DHA 
induces ER stress in TNBC cells. T3, a known ER stress inducer [52], was used as a 
positive control in this study (Fig 2.2A). 
2.4.3 CHOP is involved in DHA-induced apoptosis 
 
Since CHOP has been reported to be involved in ER stress mediated apoptosis, 
we examined if CHOP is involved in DHA-induced apoptosis. Knockdown of CHOP 
using siRNA significantly reduced the ability of DHA to induce apoptosis as detected by 
Annexin V assay (Fig 2.2C) and cleaved PARP as detected by western blotting (Fig 





Fig 2.2 DHA induces endoplasmic reticulum stress (ER stress). Cells were treated 
with DHA at different concentrations for 1 day followed by western blotting (A) or by 
RT-PCR (B) to determine presence of ER stress associated markers (B).  MDA-MB-231 
cells treated with T3 for 1 day were used as positive control for ER stress markers (A). 
Cells transfected with siRNAs to CHOP or control were treated with DHA for 1 day 
followed by Annexin V/PI analyses to determine apoptosis induction (C) or western blot 
analyses to determine protein levels (D). Data in A, B, and D are representative of at least 
two separate experiments. Data in C are depicted as mean + SD of three individual 
experiments. Pre-PARP = full length PARP and cPARP= cleaved PARP. The % of 
cleaved PARP(c PARP) is determined by densitometry analyses using Scion Image 
Software (Scion Corporation, Frederick, MD) and calculated using the formula [% of 
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cleaved PARP = cPARP/(pre-PARP + cPARP) x 100%].  * Statistically different from 
control siRNA treated with DHA, p<0.05.  
 
2.4.4 DR5 is upregulated and involved in DHA-induced apoptosis via CHOP 
 
Since several studies have shown that protein expression of the death receptor for 
DR5 is increased following ER stress and elevation of CHOP protein expression in 
induction of apoptosis by different agents, such as -TEA, T3, and synthetic triterpenoid 
methyl-2-cyano-3,12-dioxoolean-1,9-dien-28-oate (CDDO-Me) [123, 52 and 129], we 
investigated if DR5 is regulated by DHA and involved in DHA-induced apoptosis. 
Treatment of cells with increasing doses of DHA for 1 day induced elevated levels of 
DR5 protein expression (Fig 2.3A). T3 was used as positive control in this study (Fig 
2.3A). Knockdown of DR5 using siRNA resulted in a significant decrease in DHA 
induced apoptosis as detected by Annexin V analyses (Fig 2.3B) and cleaved PARP as 
detected by western blot analyses (Fig 2.3C), indicating that DHA induces DR5 
dependent apoptosis. Furthermore, data show that knockdown of CHOP using siRNA 
blocked the ability of DHA to upregulate DR5 (Fig 2.3C), demonstrating that DHA 




Fig 2.3 DR5 is involved in DHA-induced apoptosis and is regulated by CHOP.  
MDA-MB-231 and SUM159 cells were treated with DHA in different concentrations for 
1 day followed by western blot analyses to determine protein levels (A). MDA-MB-231 
cells treated with T3 for 1 day were used as positive control for DR5 (A). MDA-MB-
231 cells transfected with siRNAs to DR5, CHOP or control were treated with DHA 60 
M for 1 day followed by Annexin V/PI analyses to determine apoptosis induction (B) or 
western blot analyses to determine protein levels (C). Pre-PARP = full length PARP and 
cPARP= cleaved PARP.  The % of cleaved PARP(c PARP) is determined by 
densitometry analyses using Scion Image Software (Scion Corporation, Frederick, MD) 
and calculated using the formula [% of cleaved PARP = cPARP/(pre-PARP + cPARP) x 
100%]. DR5(L/S) refers to long and short forms of DR5. Fold increase of DR5 protein 
expression is determined by densitometry analyses using image software and normalized 
by GAPDH with the value for control as 1. Data in A and C are representative of at least 
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two separate experiments. Data in B are depicted as mean + SD of three individual 
experiments. * Statistically different from control siRNA treated with DHA, p<0.05.  
 
2.4.5 Antioxidants block DHA-induced apoptotic events. 
 
Since ROS plays an important role in DHA-induced apoptosis [130] and ROS can 
trigger ER stress [131] it was of interest to see if ROS is involved in DHA-induced 
apoptotic events in TNBC cells. Thus, we evaluated the effect of antioxidants; fat soluble 
T and water soluble NAC, on DHA-induced apoptotic events.  Pre-treatment of MDA-
MB-231 cells with T at different concentrations for 2 hrs followed by DHA treatment 
for one day significantly reduced the ability of DHA to induce apoptosis in a dose 
dependent manner as detected by Annexin V (Fig 2.4A). Furthermore, pre-treatment of 
MDA-MB-231 and SUM159 cells with T at 20 M or NAC at 10 mM for 2 hrs 
followed by DHA treatment for one day significantly reduced the ability of DHA to 
induce apoptosis as detected by Annexin V (Fig 2.4B and C) and PARP cleavage as 
detected by western blot analyses (Fig 2.4D and E). Although treatment of MDA-MB-
231 cells with T showed an increased percentage of apoptotic cells (Fig 2.4 C) it is not a 
statistically significant difference from vehicle control.    Both antioxidants markedly 
reduced the ER stress associated biomarkers GRP78 and CHOP, as well as DR5 (L/S) 
protein expression (Fig 2.4 D and E).  Although western blot data show that DR5 
protein level is increased following T treatment it is not different from the VEH control 
based on densitometric analyses performed using GAPDH levels to normalize lane loads.  
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These data demonstrate that ROS is an upstream mediator in DHA-induced apoptotic 
events. Importantly, these data indicate that both water soluble and fat soluble 
antioxidants are antagonistic to DHA’s anticancer pro-apoptotic properties.  
 
Fig 2.4 Antioxidants  block DHA-induced apoptotic events. Pre-treatment of MBA-
MB-231 cells with T at indicated concentrations for 2 hrs followed by DHA treatment 
for 1 day significantly reduced the ability of DHA to induce apoptosis as detected by 
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Annexin V/PI analyses (A). MDA-MB-231 and SUM159 Cells pre-treated with T or 
NAC for 2 hrs were treated with DHA 80 M and 60M, respectively, for 1day followed 
by Annexin V/PI analyses to determine apoptosis induction (B and C) and western blot 
analyses to determine protein levels (D and E). Pre-PARP = full length PARP and 
cPARP= cleaved PARP.  DR5 (L/S) refers to long and short forms of DR5. Fold 
increase of DR5 protein expression is determined by densitometry analyses using Scion 
Image Software (Scion Corporation, Frederick, MD) and normalized by GAPDH with the 
value for control as 1. Data in A, B and C are depicted as mean + SD of three individual 
experiments. Data in D and E are from two separate experiments.* Statistically different 
from DHA treatment alone, p<0.05.  
  
2.4.6T3 and DHA work cooperatively to induce apoptotic events.  
 
Since previous data show that T3 induces apoptosis via activation of ER stress 
mediated CHOP/DR5 pro-apoptotic signaling events in MDA-MB-231 and MCF-7 
human breast cancer cells [52], it was of interest to see the effect of this form of vitamin 
E on DHA induced apoptosis. T3 induced apoptosis in both cell lines in a dose-
dependent manner at levels of 10 M and above (Fig 2.5A and B). Thus, when cells were 
co-treated with sub-apoptotic doses of T3 (namely, treated with a level of T3 that does 
not induce apoptosis within one day) plus DHA for one day to evaluate cooperative 
apoptotic effects, data show that the combination of T3 + DHA acts cooperatively to 
induce apoptosis as detected by Annexin V (Fig 2.5 C and D) and cleaved caspases 8, 9 
and PARP (Fig 2.5 E). Furthermore, data in Fig 2.5 F and G show that T3 at different 
concentrations enhanced DHA-induced apoptosis in both cell lines in comparison with 
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T3 and DHA alone. Moreover, data from western blot analyses show that combination 
of DHA + T3 enhanced ER stress as detected by ER stress biomarkers, GRP78 and 
CHOP, and ER stress associated DR5(L/S) protein expression (Fig 2.6 A). siRNAs to 
CHOP or DR5 reduced the combination pro-apoptotic effect of DHA + T3 (Fig 2.6 B), 
and siRNA to CHOP reduced combination (DHA + T3) upregulation of DR5 protein 
expression (Fig 2.6 C), demonstrating that ER stress mediated CHOP/DR5 pro-apoptotic 







Fig 2.5 T3 and DHA work cooperatively to induce apoptosis MDA-MB-231 and 
SUM 159 cells were treated with different doses of T3 as indicated for 1 day followed 
by Annexin V/PI analyses to determine apoptosis induction (A and B).  The cells were 
treated with sub-apoptotic doses of T3 and DHA for 1 day followed by Annexin V/PI 
analyses to determine apoptosis induction (C and D) or western blot analyses to 
determine protein levels (E). MDA-MB-231 and SUM159 cells were co-treated with 
different doses of T3 + apoptotic doses of DHA as indicated for 1 day followed by 
Annexin V/PI analyses to determine apoptosis induction (F and G). Pre-PARP = full 
length PARP and cPARP= cleaved PARP. Data in A, B, C, D, F and G are depicted as 
mean + SD of three individual experiments. Data in E are representative of data 
generated in at least two separate experiments. * Statistically different from vehicle 








Fig 2.6 ER stress is involved in T3 + DHA induced apoptosis MDA-MB-231 and 
SUM159 cells were co-treated with T3 + DHA for 1 day followed by western blot 
analyses to determine the ER stress marker protein expression (A). Cells transfected with 
siRNAs to DR5, CHOP or control were treated with a combination of T3 + DHA for 1 
day followed by Annexin V/PI analyses to determine apoptosis induction (B) and western 
blot analyses to determine protein levels (C). Pre-PARP = full length PARP and cPARP= 
cleaved PARP.  The % of cleaved PARP(c PARP) is determined by densitometry 
analyses using image software and calculated using the formula [% of cleaved PARP = 
cPARP/(pre-PARP + cPARP) x 100]. DR5(L/S) refers to long and short forms of DR5. 
Fold increase of DR5 protein expression is determined by densitometry analyses using 
image software and normalized by GAPDH. Data in B are depicted as mean + SD of 
three individual experiments. Data in A and C are representative of data generated in at 
least two separate experiments. * Statistically different from control siRNA transfected 




2.4.7 The effects of T and T3 on DHA induction of ROS 
 
Since T and T3 exhibited completely opposite effects on DHA-induced ROS 
dependent apoptosis, it was of interest to determine the impact of T3 and T on DHA 










Fig 2.7 DHA induces ROS. MDA-MB-231 and SUM159 cells were treated with DHA at 
60 and 40 M, respectively (A), T3 at 5 M (B), T at 20 M + DHA at 60 and 40 M, 
respectively (C), and T3 at 5 M + DHA 50M and 20M, respectively (D) for 3 hrs. 
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ROS intensity was determined by FACS analyses after staining the cells with special 
ROS indicator dye- H2DCF-DA. 
 
 
Treatment of both cell lines with DHA for 3 hours induced elevated levels of ROS 
(Fig 2.7A). In contrast, treatment of both cell lines with T3 for 3 hours had no effect on 
ROS induction (Fig 2.7B). Treatment of cells simultaneously with T + DHA for 3 hours 
reduced ROS induction in comparison with DHA alone (Fig 2.7C). While treatment of 
cells with T3 + DHA for 3 hours showed neither enhancement nor diminution of DHA-
induced ROS generation (Fig 2.7D). These data demonstrated that; (i) T3 is not acting as 
either a pro-oxidant or antioxidant in DHA-induced apoptosis, (ii) T is acting as an 
antioxidant capable of blocking DHA’s induction of ROS, which is critical for its pro-
apoptotic effects on TNBC cells, and (iii) T3 enhances DHA-induced apoptosis via a 
ROS independent mechanism.  
2.5 Discussion 
 
DHA, a dietary component with known anti-inflammatory and cardioprotective 
benefits, is a widely used supplement. Data show that DHA at physiologically relevant 
levels induces apoptosis in human breast cancer cells (Fig 2.1 A), and DHA did not 
induce apoptosis in normal human mammary epithelial cells (data not shown), using the 
same conditions as described in Fig 2.1A. Those data indicate that DHA exhibits a 
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selective anticancer property and hold as a nontoxic promising anticancer agent. The 
novel findings in this study are: (i) DHA induces apoptosis in TNBC cells via activation 
of ER stress mediated CHOP/DR5 pro-apoptotic events involving both caspase-8 and 9, 
(ii) ROS is a necessary  upstream mediator of DHA-induced apoptosis, (iii) vitamin E in 
the  form of T blocks DHA-induced ROS formation and apoptotic events, indicating a 
potential antagonistic effect of supplemental T on DHA’s anticancer action, and (iv) 
T3, a  form of vitamin E that exhibits anticancer activity, enhances DHA-induced 
apoptotic events. Taken together, our data, for the first time, demonstrate that ERS-
mediated CHOP/DR5 pro-apoptotic signaling events are involved in DHA-induced 
apoptosis, and that two different vitamin E forms have the potential to either block or 
enhance the anticancer actions of DHA.    
Targeting the homeostatic status of the endoplasmic reticulum has been reported 
to be an effective way to trigger cancer cells to undergo apoptosis [132]. Several natural 
compounds have been reported to induce apoptosis via induction of ER stress, such as 
curcumin [133], T3 [52], and epigallocatechin gallate (EGCG) [134]. DHA has been 
reported to induce ER stress in colon cancer cells [128]. However, whether or not ER 
stress is critical for DHA-induced apoptosis has not been addressed. CHOP, as a 
transcription factor for promoting DR5 transcription [135], has been reported to be a 
critical mediator in ER stress mediated apoptosis, in part, via increased levels of DR5 
[136]. Here, for the first time, we report that DHA induces ER stress in TNBC cells and 
ER stress-mediated increased expression of CHOP is involved in DHA-induced apoptosis 
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via upregulation of DR5, leading to activation of death receptor dependent caspase-8 and 
-9 apoptotic cascades.  
DHA is the longest, most unsaturated, and hence, most oxidizable fatty acid 
commonly found in nature [137]. Its pro-oxidant property is one of the mechanisms of 
DHA action in its ability to induce apoptosis [138]. However, how ROS mediates DHA-
induced apoptosis has not been elucidated. ROS has been reported to trigger ER stress, 
leading to apoptosis [139]. Here, for the first time, we report that ROS mediates DHA-
induced apoptosis via upregulation of ER stress-mediated CHOP/DR5 in TNBC cells. 
Evidence supporting this conclusion include: (i) DHA induces increased levels of ROS, 
(ii) antioxidants T and NAC blocked the DHA’s ability to induce apoptosis and blocked 
DHA’s ability to increase levels of ER stress biomarkers GRP78 and CHOP, and DR5, 
and (iii) T blocked DHA’s ability to increase levels of ROS.  
An additional important finding in this study is that different vitamin E forms 
exhibit opposite roles in DHA-induced apoptosis. T functions as an antioxidant and 
directly antagonizes DHA’s anticancer actions. In striking contrast, T3 exhibits neither 
pro-oxidant nor antioxidant properties, and exhibits a marked beneficial combination 
effect on DHA’s pro-apoptotic actions. These findings further support the notion that 
different forms of vitamin E possess distinctly different anticancer properties, and 
secondly, they provide important insights into how DHA’s application in the clinic for 
cancer prevention or treatment will need to take into account other dietary influences. 
Further studies will be required to ascertain if limitation of T consumed from 
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supplements and food sources, and/or supplement with T3 impacts DHA’s anticancer 
efficacy.   
It appears that the pro- or anti-oxidant properties of vitamin E depend on not only 
the form of vitamin E, but also the cell type and experimental conditions. For example, 
Kannappan et al. reported that T3 induced upregulation of DR5 via ROS in human colon 
cancer cells [140], and Nowaket al. reported that T3 protected against oxidant injury in 
renal proximal tubular cell [141]. Data show that T3 exhibited neither pro- nor anti-
oxidant properties in TNBC (Fig 2.7 B), even when apoptotic doses were used (up to 20 
M, data not shown).  
How T3 cooperates with DHA to induce apoptosis is not entirely clear. Data 
showing that T3 did not enhance DHA-induced ROS (Fig 2.7 D) rules out the possibility 
that T3 enhances DHA-induced apoptosis via a pro-oxidation impact. Recently, we have 
studied the role of ceramide in T3-induced ER stress mediated apoptosis. Data show that 
T3 induces elevated intracellular levels of ceramide and that the chemical inhibitors of 
de novo ceramide synthesis pathways were capable of blocking T3-induced apoptosis 
and ER stress-mediated CHOP/DR5 pro-apoptotic events [56], indicating that ceramide 
generated from de novo ceramide synthesis pathway are involved in T3-induced 
apoptosis. Since both ceramide generated from de novo ceramide synthesis pathway 
[142] and ROS can trigger ER stress [139], it is possible that T3 cooperates with DHA 
to induce apoptosis via a combination of increased ROS and increased ceramide. Further 
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studies will be needed to address this possibility. Based on the data presented here and 
our unpublished studies, a schematic diagram of proposed signaling events in DHA 
induced apoptosis of TNBC and the distinct role of T and T3 on DHA pro-apoptotic 





Fig 2.8 Proposed signaling events in DHA induced apoptosis of TNBC and the role 
of T and T3 on DHA pro-apoptotic actions. Based on data presented here and other 
data generated by our lab (unpublished), we propose the following signaling events in 
DHA-induced apoptosis and the role of T and T3 in DHA pro-apoptotic actions: (i) 
DHA alone induces elevated levels of ROS, leading to induction of ER stress, (ii) DHA 
upregulates DR5 protein expression via ER stress mediated CHOP, (iii) DHA 
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upregulation of DR5 triggers caspase-8 and caspase-9 dependent apoptotic cascade, (iv) 
T blocks DHA’s ability to induce ROS thus blocking DHA’s pro-apoptotic actions via 
its antioxidant property, and (v) T3 cooperates with DHA to produce ER stress and 
downstream pro-apoptotic actions. Unbroken arrows indicate data generated in the 





In summary, our data show that DHA induces apoptosis in TNBC cells via 
activation of ER stress mediated CHOP/DR5 pro-apoptotic events, in which ROS is an 
upstream mediator. T, acting as a classic antioxidant, blocks DHA pro-apoptotic action, 
while T3 enhances DHA pro-apoptotic action via a ROS-independent mechanism. These 
studies not only provide novel insights into a better understanding of the mechanisms 
underlining DHA-induced apoptosis but also provide in vitro evidence to support the use 
of T3, and avoidance of T, to improve DHA anticancer actions. These data provide a 
















Chapter 3 Gamma-tocotrienol cooperates with docosahexaenoic acid to 
eliminate human triple negative breast tumor initiating cells 
 
3.1 Abstract  
 
DHA eliminates ALDH+ cells and inhibits mammosphere formation, two 
indicators of tumor initiating cells (TICs), as well as suppresses pStat-3 and its 
downstream mediators c-Myc, and cyclin D1 in human TNBC cell lines. T3 
cooperatively enhances DHA’s actions. siRNA to Stat-3 reduced ALDH+ cells as well as 
suppressed pStat-3/total Stat-3, c-Myc and cyclin D1, suggesting that DHA and T3 











3.2  Introduction 
Despite progress in treatment of breast cancer, TNBC, a sub-type of breast 
cancers that lack expression of ER, PR and Her-2, present a special therapeutic challenge 
due to their aggressive clinical course and lack of targeted therapy [2]. TNBCs comprise 
15-20% of human breast cancers in Western countries and are associated with a low 5-
year survival rate [2]. Due to lack of molecular targets, the only therapeutic option 
currently available for TNBC is chemotherapy. DNA damaging drugs such as 
doxorubicin, cisplatin and taxol are used as standard-of-care. Although TNBC is initially 
sensitive to chemotherapy, prognosis remains poor due to tumor recurrence, drug 
resistance, and toxicity associated with chemotherapy [2].   
TICs or CSCs are a minor population of tumor cells that exhibit both self-renewal 
and differentiation capabilities as well as play key roles in metastasis, drug resistance and 
tumorigenic properties [9]. Transplantation of limiting numbers of TICs has been shown 
to regenerate breast tumor in NOD/SCID mice [11], demonstrating that TICs possess 
tumorgenic properties. Standard therapies, such as chemotherapy and radiation therapy, 
reduce tumor size via targeting bulk tumor cells, but not TICs, leading to tumor 
recurrence associated with metastasis and treatment resistance [143]. Thus, targeting 
TICs is considered a promising strategy for cancer prevention and treatment.   
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DHA is a long chain polyunsaturated omega-3 fatty acid (22:6 n-3), obtained 
from cold water fishes. DHA is being investigated as a potential dietary-based agent for 
cancer prevention including breast cancer [91]. DHA has been shown to exhibit multiple 
anticancer mechanisms of action, including inhibition of cell proliferation [ 144 ], 
metastasis [145], blood vessel formation [146], inflammation [147], as well as induction 
of cell cycle arrest [148], inhibition of differentiation [149] and induction of apoptosis 
[144]. Recent data show that DHA possesses the ability to inhibit mammary tumor 
formation in a mouse polyoma virus middle T antigen induced mammary cancer mouse 
model [95], to inhibit formation of  mammospheres and to induce apoptosis of TIC-
enriched human colon cancer cells [37], suggesting  potential for eliminating TICs.  
The term vitamin E encompasses a family of structurally distinct chemicals that 
are classified as tocopherols and tocotrienols in which there are four sub-forms, 
and [38]. Their anticancer actions have been widely studied [38]. Accumulating 
data show that gamma-tocotrienol (T3), found in palm oil, cereal grains and rice bran as 
well as tocotrienol supplements, possess anticancer actions in vitro and in vivo [52]. 
Recent data show that T3 possesses anti-TIC properties in human prostate and breast 
cancer cells [67, 150]. 
Published data from our lab showed that DHA induced apoptosis and that T3 
enhanced DHA pro-apoptotic actions in TNBC cells [72]. Objectives of this study are to 
evaluate the ability of DHA alone and in combination with T3 to eliminate TICs and to 
investigate the mechanisms of action involved using human TNBC cells in culture.   
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3.3 Materials and Methods 
3.3.1 Cell Culture and Reagents 
 
Human TNBC cell lines MDA-MB-231, SUM159 and SUM149 [121] were used 
in this study. The sources and culture conditions of these cell lines were previously 
described for MDA-MB-231 human breast cancer cells [122], as well as SUM159 and 
SUM149 human breast cancer cells [151]. For experiments, fetal bovine serum (FBS) 
was reduced to 2% in all media to mimic in vivo conditions and cells were allowed to 
attach overnight before treatment initiation. DHA was purchased from Sigma-Aldrich. 
T3 was a gift from the Malaysian Palm Oil Board (Kuala Lumpur, Malaysia). Both 
DHA and T3 were dissolved in 1:4 DMSO/ethanol at 40 mM as stock solutions. 
Equivalent levels of 1:4 DMSO/ethanol was used as vehicle control (VEH).  
3.3.2  Western blot analyses 
 
Western blot analyses were conducted as described previously [122]. Primary 
antibodies to the following proteins were used in this study: c-Myc, and Cyclin D1 (Santa 
Cruz Biotechnology, Santa Cruz, CA), pStat-3 (Tyr705) and Stat-3 (Cell Signaling), and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH, made in house). Secondary 
antibodies used included: horseradish peroxidase conjugated goat-anti-rabbit and rabbit-
anti-mouse (Jackson Immunoresearch, Rockford, IL). 
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3.3.3  Analysis of aldehyde dehydrogenase activity and sorting of ALDH+ 
population 
ALDH activity was determined using an Aldefluor assay kit (Stem Cell 
Technologies, Inc, Vancouver, BC, Canada) according to the manufacturer’s instructions.  
Aldefluor fluorescence was detected by fluorescence activated cell sorting (FACS) using 
a FL1 detector in a LSR Fortessa flow cytometer and analyzed using BD FACSDiVa 
software (version 6.1.3). ALDH+ cells were sorted using a FACS Aria cell sorter (Becton 
Dickinson, Palo Alto CA). 
3.3.4  Mammosphere formation assay 
 
Unsorted and sorted ALDH+ cells were assessed for ability to form 
mammospheres using established mammosphere formation conditions [ 152 , 153]. 
Briefly, cells were plated in 6-well ultra-low attachment plates at 100,000 cells/well 
under mammosphere formation conditions described in [153] followed by different 
treatments  for 7 days. After counting the number of primary mammospheres, the 
mammospheres were disassociated into single cell suspensions and re-cultured for 
another 7 days without treatments to determine the number of secondary mammospheres.  
Then, the secondary mammosphere were disassociated and seeded back for another 7 
days to determine numbers of tertiary mammospheres. Counting mammospheres of three 
generations were performed manually under 10 X microscopic examination.  




Data were analyzed using one-way analysis of variance followed by the Turkey 
test for comparison of more than two treatments or a two-tailed Student t-test for 
comparison between two treatments to determine statistical differences. p < 0.05 was 
considered as statistically  significantly  different.  
3.4 Results 
 
3.4.1  DHA eliminates ALDH+ population in TNBC cells  
 
ALDH+ has been shown to be a TIC marker in certain breast cancer cell lines 
[14]. Ginestier et al. have demonstrated that only ALDH+ cells from human breast cancer 
tumors can be xenotransplanted into NOD/SCID mice and serially passaged in vivo [14], 
whereas ALDH negative cells can not be serially passaged [14]. FACS analyses based on 
ALDH+ marker show that TNBC cell lines SUM 159, SUM 149 and MDA-MB-231 
contain 4.7 ± 1.11%, 7.1 ± 0.56% and 2.0 + 0.4% ALDH+ cells, respectively (Fig 4.1a). 
Treatment of the ALDH+ cells from these three cell lines with different concentrations of 
DHA for 18 hrs induced a dose-dependent reduction of the ALDH+ cells (Fig 4.1b). 
Since ALDH+ is an established TIC marker in SUM 159 cells [14] and has been studied 
in SUM 149 cells as TIC marker [18], as well as in MDA-MB-231 cells as one of several 
TIC markers (CD44+/CD24-/ALDH+) [154], the data presented in Fig 1b suggest that 





Fig 3.1 DHA eliminates ALDH+ population in TNBC cells. A. Percentages of ALDH+ 
population in three TNBC cell lines were determined using ALDH activity assay. Data 
are representative of one of three repeats. B. Percentages of ALDH+ population in cells 
treated with different concentrations of DHA for 18 hrs were determined by ALDH 
activity assay. Data are depicted as mean ± S.D. of three independent experiments. 
*significantly different from VEH, p<0.05.  
 
3.4.2  DHA inhibits mammosphere formation  
 
To further determine if DHA eliminates breast TICs we evaluated the effects of 
DHA on mammosphere formation, an established functional characteristic of TICs, using 
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serial mammosphere formation assays. Unsorted SUM 159 and MDA-MB-231 cells were 
treated with different concentrations of DHA for 7 days followed by counting the number 
of primary mammosphere. The numbers of secondary and tertiary mammospheres were 
determined after the primary and secondary mammospheres were diassociated and re-
cultured for 7 days, respectively (Note: cells were treated with DHA for 7 days only in 
primary mammosphere formation). Vehicle treated cells served as control. DHA induced 
a dose-dependent reduction of the number of mammospheres in three generation in both 
cell lines (Fig 3.2A and 3.2B). Since the ALDH+ population has been established as TIC-
enriched population in SUM 159 cells, we further determine if DHA inhibits serial 
mammosphere formation in the ALDH+ population sorted from SUM 159 cells. Data 
show that DHA induced a dose-dependent reduction of numbers of primary 
mammospheres of ALDH+ cells (Fig 3.2C). These data demonstrated that DHA has a 












Fig 3.2 DHA inhibits serial mammosphere formation. (A, B) Serial mammosphere 
formation assays were performed using unsorted SUM 159 and MDA-MB-231 TNBC 
cells cultured with different concentrations of DHA in the 7-day primary mammosphere 
formation assay. Secondary and tertiary mammosphere formation assays were conducted 
as described in the Materials and Methods section without treatment. (C) Primary 
mammosphere formation assay was performed using sorted ALDH+ cells treated with 
different concentrations of DHA for 7 days. The numbers of mammospheres are 
presented as mean ± S.D. of three individual experiments. *significantly different from 
VEH treatment, p<0.05.  
 
3.4.3 DHA suppresses Stat-3 signaling  
  
Stat-3 has been reported to contribute to maintenance of TICs in breast cancers 
[155]. To gain an understanding of the molecular mechanisms by which DHA eliminates 
TICs, we determined the effects of DHA on protein levels of pStat-3 and total Stat-3 
(tStat-3) as well as the status of two Stat-3 target proteins: c-Myc, and cyclin D1. 
GAPDH served as sample loading controls. DHA suppressed levels of pStat-3, c-Myc, 
and cyclin D1 with no effect on total Stat-3 protein expression in both SUM 159 and 
MDA-MB-231 cell lines (Fig 3.3 A). Furthermore, DHA at 30 M suppressed pStat-3, c-
Myc and cyclin D1 protein levels in ALDH+ cells sorted from SUM 159 cells (Fig 3.3 
B). These data suggest that DHA suppression of cyclin D1 and c-Myc via Stat-3 




Fig 3.3 DHA suppresses pStat-3, cyclin D1 and c-Myc protein levels in TNBCs.  (A 
and B) Western blot analyses were conducted to determine the effect of DHA on pStat-3, 
tStat-3, c-Myc and cyclin D1 protein levels in unsorted cells (A) and in ALDH+ sorted 
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SUM 159 cells (B). GAPDH was used as loading control. Data are representative of two 
or more independent experiments. 
   
3.4.4 Stat-3 signaling contributes to maintenance of ALDH+ population and 
expression of cyclin D1 and c-Myc 
To determine if Stat-3 contributes to the expression of c-Myc and cyclin D1 
proteins, knock down studies were conducted using SUM 159 cells. SUM 159 cells were 
transfected with siRNA to Stat-3 or irrelevant siRNA for 18 hours, followed by 
determining numbers of ALDH+ cells.  siRNA to Stat-3 reduced the number of ALDH+ 
cells from 5.1% (in irrelevant siRNA treated cells) to 0.8% (Fig 3.4A & 3.4B), clearly 
showing a role for Stat-3 in survival of ALDH+ cells. Western blot analyses show that 
siRNA to Stat-3 knocks down total Stat-3 and pStat-3, as well as c-Myc and cyclin D1 
protein levels (Fig 3.4 C), confirming that c-Myc and cyclin D1 are downstream mediator 




Fig 3.4 Stat-3 signaling contributes to numbers of ALDH+ cells as well as levels of 
cyclin D1 and c-Myc protein.  (A and B) The percentages of ALDH+ population in 
SUM 159 cells transfected with siRNAs to Stat-3 or control siRNA were determined by 
ALDH activity assay. Data are depicted as mean ± S.D. of three independent 
experiments. (C) Western blot analyses were performed to determine pStat-3, tStat-3, c-
Myc, and Cyclin D1 protein levels. Fold decrease of c-Myc protein expression was 
determined by densitometry analyses using Scion image software and normalized to 
GAPDH with the value for control as 1. GAPDH served as control. Data are 




3.4.5  T3 acts cooperatively with DHA to eliminate TICs and suppress Stat-3 
signaling 
 
Previously, we reported that T3 possesses the ability to inhibit mammosphere 
formation and reduce ALDH+ population as well as suppress Stat-3 signaling in 
tamoxifen and doxorubicin drug resistant breast cancer cell lines [36]. Since T3 has been 
reported to cooperate with DHA to induce apoptosis in TNBC cell lines [72], it was of 
interest to determine if T3 cooperatively enhances DHA elimination of TICs and 
suppression of Stat-3 signaling. First, we evaluated the ability of T3 to eliminate the 
ALDH+ population in SUM 159 cells. Data show that T3 at 15 M significantly 
reduced the numbers of ALDH+ cells (Fig 3.5A). Next, SUM 159 cells were treated with 
DHA and T3 separately and in combination for 18 hours, followed by assessing 
numbers of ALDH+ cells. The combination of DHA at 20 M and T3 at 5 M 
significantly reduced the number of ALDH+ cells in comparison to vehicle control and 
single treatments with DHA and T3 (Fig 3.5 B). Treatment of SUM 159 and MDA-MB-
231 cells with DHA plus a sub-optimal dose of T3 significantly reduced mammosphere 
formation (Fig 3.5 C and D). Taken together these data show that DHA and T3 act 
cooperatively to reduce the numbers of ALDH+ cells as well as mammosphere formation 
in TNBC cells. Furthermore, western blot analyses show that the combination of DHA + 
T3 cooperatively reduced levels of pStat-3, c-Myc, and cyclin D1 (Fig 3.5 E), 












Fig 3.5 DHA and T3 cooperatively eliminate ALDH+ population, inhibit 
mammosphere formation, and suppress Stat-3 signaling. (A) The percentages of 
ALDH+ population in SUM 159 cells treated with different concentrations of T3 for 18 
hrs were determined by ALDH activity assay. (B) The percentages of ALDH+ population 
in SUM 159 cells treated singly with 5 M T3 or 20 M DHA and in combination for 
18 hrs were determined by ALDH activity assay. (C and D) Serial mammosphere 
formation assays were performed using unsorted MDA-MB-231 cells treated singly with  
T3 or DHA alone and in combination in 7 day primary mammosphere formation assays. 
Secondary and tertiary mammosphere assays were conducted without further treatments 
as described in the Materials and Methods section. (E) Western blot analyses were 
performed to determine pStat-3, tStat-3, c-Myc, and Cyclin D1 protein levels in lysates 
from MDA-MB-231and SUM 159 cells treated with 5 M T3, 20 M DHA, or with 
combination for 18 hours. Data in a-d are depicted as mean ± S.D. of three independent 
experiments. *significantly different from single treatments, p<0.05. Data in E are 





Previously, we reported that T3 possesses the ability to eliminate TICs in 
tamoxifen and doxorubicin resistant human breast cancer cell lines [36] and can 
cooperatively enhance DHA-induced apoptosis in TNBC cells [72]. In this study, we 
investigated the ability of DHA alone and in combination with T3 to eliminate TICs 
using human TNBC cells, and explored their molecular mechanisms of action. Novel 
findings from this study include: (i) DHA eliminates TICs as determined by the ability of 
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DHA to reduce the ALDH+ population and to inhibit mammosphere formation, (ii) the 
ability of DHA to eliminate TICs is correlated with the ability of DHA to reduce levels of 
pStat-3 as well as c-Myc and cyclin D1, (iii) siRNA to Stat-3 reduced the number of 
SUM159 ALDH+ cells and reduced pStat-3, c-Myc, and cyclin D1, suggesting that Stat-3 
is necessary for maintaining ALDH+ population and contributes to the expression of c-
Myc and cyclin D 1, and (iv) T3 cooperatively enhances DHA elimination of TICs and 
suppression of Stat-3 signaling. Taken together, these data provide in vitro evidence that 
DHA and DHA + T3 possess potential to eliminate TICs of human TNBC via 
suppression of Stat-3 signaling.  
Accumulating in vitro and in vivo data support the notion that traditional cancer 
therapeutics such as chemotherapy and radiotherapy mainly target non-TICs (bulk of the 
tumor cells) and leave behind small numbers of TICs, which account, in part, for tumor 
recurrence, multi-drug resistance, and metastasis [152, 156 and 157]. Thus, targeting 
TICs is an emerging novel strategy for those challenged breast cancers including TNBC.    
Several natural compounds have been shown to possess in vitro and/or in vivo anti-TIC 
properties including curcumin [158], sulforaphane and piperine [31], galiellalactone [32], 
sesquiterpene lactone parthenolide [159], soy isoflavone genistein [160], blueberry [161], 
T3 [36] and DHA [37], proving new opportunity as anticancer agent for cancer 
prevention and treatment. The present study further confirms that DHA possesses the 
potential to eliminate TICs, and for the first time, suggest that a combination of two 
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generally recognized as safe food based agents can act cooperatively to eliminate TICs,  
offering a potential treatment.    
Stat-3 is a transcription factor [24] that is involved in cell proliferation, 
metastasis, and cell survival [25]. In response to cytokines and growth factors, Stat-3 
family members are phosphorylated by receptor-associated kinases followed by forming 
homo- or heterodimers that translocate to the cell nucleus, where they function as 
transcription factors [24]. It has been reported that 50% of breast cancers express 
phosphorylated Stat-3, in which basal-like breast cancer cells express even higher levels 
[26, 27]. pStat-3 has been shown to be highly expressed in CD44+/CD24- populations 
and required for tumor cell growth [27], as well as involved in maintaining TICs in breast 
cancer cells, including SUM 159 cells [27]. Importantly, normal and benign breast cells 
do not express pStat-3 [26]. Thus, promising in vitro and in vivo data point to Stat-3 
signaling as a target for TIC elimination in basal-like breast cancer, including TNBC.   
Some of the natural compounds that have been shown to possess in vitro and/or in 
vivo anti-TIC properties exhibit the ability to suppress Stat-3 signaling [36, 158 and 161]. 
In this study, for the first time, we demonstrated that DHA and DHA + T3 possess the 
ability to suppress Stat-3 signaling. How these two nutrients suppress Stat-3 signaling is 
not known and is worthy of further study.  
Although pre-clinical studies provide evidence supporting omega-3 fatty acids 
obtained from cold water fishes, flax, walnuts and soybeans, as a potential dietary-based 
agent for breast cancer prevention, the epidemiologic studies have been inconclusive due, 
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at least in part, to the complex interactions among dietary lipids [162]. Clinical studies 
show that high level intake of EPA+DHA (at least 2.52 g /d) is necessary for anticancer 
efficacy [163]. However, studies report that high intakes of DHA/EPA have the risk to 
extend bleeding time [164]. Thus, a strategy that can enhance DHA anticancer efficiency 
is needed to increase the potential of omega-3 use as an anticancer agent. T3 possesses 
low in vivo bioavailability and the maximal concentration that can be transiently reached 
is considered to be approximately 5 M [165], which is a non-effective dose when tested 
in vitro for its anticancer actions. T3, at the achievable concentration (5 M), was shown 
to cooperate with DHA in vitro to induce apoptosis in TNBC cells in previous study [72], 
and to eliminate TICs in a recent study, providing a novel strategy that can maximize the 
anticancer efficacy of DHA and T3 as an effective dietary cancer therapeutic. These 
studies also provide a sound rationale for further investigation of this nutrient-based 
combination for clinic use.  
In summary, present data showing that DHA alone and the combination of DHA 
+ T3 eliminated human TNBC TICs and suppressed Stat3 signaling provides in vitro 
evidence to support the use of this nutritional combination for treatment of TNBC. 
Chapter 4   Evaluation of the anticancer properties of vitamin E 
compounds  




Gamma- and delta-tocopherols (T and T) and -tocotrienols (T3 and T3) 
decrease the number of tumor initiating cells (TICs) in human SUM 159 triple negative 
breast cancer cells (TNBCs) in vitro.  In striking contrast, RRR--tocopherol (T) and 
synthetic vitamin E [all-racemic--tocopherol (all-rac-T)] enhance the number of 
TNBC TICs. TICs were identified as the aldehyde dehydrogenase activity positive 
(ALDH+) sub-population and by their ability to form mammospheres in vitro. All of the 
anti-TIC vitamin E compounds (i.e. T and Tas wellasT3 and T3) suppressed pStat-
3 and downstream mediators Cyclin D1 and c-Myc; whereas, T and all-rac-T 
enhanced pStat-3, Cyclin D1 and c-Myc. Taken together, the data show that vitamin E 
compounds exhibit different effects on TNBC TICs and suggest that Stat-3 signaling 
plays an important role in these events. 
4.2 Introduction  
 
One of the daunting challenges for treatment of breast cancer is triple negative 
breast cancers (TNBCs), a sub-type of breast cancer that accounts for ~15-20% of breast 
cancers in Western countries [2]. Due to a lack of effective targeted therapy, the only 
treatment available for this type of cancer is chemotherapy [2]. TNBCs are associated 
with poor prognosis and a low five year survival rate due, in part, to a high rate of tumor 
recurrence, multi-drug resistance, metastasis, and therapeutic toxicity [2]. It is urgent to 
identify low to non-toxic anticancer agents that successfully treat TNBCs. Accumulating 
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data suggest that successful treatment regimens need to eliminate both tumor bulk and 
tumor initiating cells (TICs)/cancer stem cells (CSCs) [143]. 
TICs/CSCs are defined as a small population in cancer cells, that exhibit normal stem 
cell characteristics of self-renewal and differentiation; as well as, the properties of metastasis, 
tumorigenesis and drug resistance [9]. Based on the TIC/CSC hypothesis, TICs are 
responsible for cancer initiation, metastasis, drug resistance and cancer recurrence [11]. Most 
current cancer therapies such as chemotherapy or radiation therapy, eliminate 
differentiated cancer cells that make up the bulk of tumor cells, also called non-TICs, but 
not TICs [12]. Accumulating data show that chemotherapy and radiation can increase the 
number of TICs [16]. This may explain the failure of current cancer therapies in some 
subtypes of breast cancer, including TNBCs. Thus, identification of non-toxic agents that 
eliminate TICs as well as non-TICs holds potential for successful treatment of the breast 
cancers, where current treatments are limited. 
Certain naturally occurring bioactive compounds, such as curcumin [30], 
sulforaphane and piperine [31], galiellalactone [32], sesquiterpene lactone parthenolide 
[33], soy isoflavone genistein [35], blueberry [35], and docosahexaenoic acid (DHA) 
[95], have become attractive for both prevention and therapy of cancers due to their low 
toxicity and potential to eliminate both bulk of tumor cells and TICs. T3, one form of 
vitamin E, has been reported to eliminate TICs in prostate and breast cancer cell lines 
[36, 67].  
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There are eight naturally occurring vitamin E compounds in plants: four 
tocopherols (, , , and ) and four tocotrienols (, , , and ) [38]. Various vitamin E 
forms have been studied for their anticancer properties [38]. Early studies were focused 
on T due to its highest serum levels over other vitamin E forms in humans [38]. 
However, little to no effect on either cancer prevention or therapy has been observed [38, 
50]. Instead, the recently published follow-up study of prospective clinic trail using 
selenium and synthetic vitamin E for prostate cancer prevention, namely SELECT, 
showed higher prostate cancer incidence in subjects given the all-rac-αT supplement 
[50]. More recent studies have focused on the - and -forms of tocopherol and 
tocotrienol. Accumulating data show that these forms of vitamin E possess anticancer 
actions both in vitro and in vivo [38]. T3 and T3 are enriched in cereal grains, wheat 
germ, rice bran and palm oil [38]. The unique anticancer features of T3 and T3 include: 
induction of cell cycle arrest [47], down-regulation of telomerase activity [166] and 
induction of apoptosis [47], as well as anti-angiogenic and anti-metastasis activities [47]. 
T and T are enriched in soybean oil, corn oil and castor oil [57]. These two tocopherols 
have been shown to inhibit tumor growth in a lung xenograft model, whereas αT did not 
[59]. These two forms of tocopherol exhibit the ability to inhibit cell growth by arresting 
the cell cycle at the S phase as well as suppressing cyclin D1 and cyclin E protein levels 
[61]. Tocopherols have been shown to induce apoptosis, involving activation of caspases-
9 and -3, as well as interruption of the synthesis of sphingolipids [57]. A study from our 
lab showed that γT induces human breast cancer cells to undergo apoptosis via a death 
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receptor 5 (DR5) pathway [56]. Several in vivo studies have shown that both and  forms 
of tocopherols and tocotrienols possess the ability to inhibit tumor formation and growth in 
preclinical xenograft mouse models [52, 59].  
In this study, we evaluated the effects of the most studied forms of vitamin E on 
TICs in TNBC cells and found that different forms of vitamin E compounds exhibit 
differential effects on TICs and that the Stat-3 signaling pathway plays an important role 
in the anticancer effects.    
4.3 Materials and Methods 
 
4.3.1 Reagents  
all-rac-T was purchased from Sigma Chemical Co (St. Louis, MO, USA). T 
and T were gifts from TAMA Biochemical in Japan. T was isolated from a natural 
mixed tocopherols concentrate (COVI-OX T-95, BASF, the chemical company, Illinois, 
USA). γT3 was a gift from the Malaysian Palm Oil Board (Kuala Lumpur, Malaysia) and 
T3 was a gift from American River Nutrition, Inc (Hadley, MA).  
4.3.2 Cell culture   
Human breast cancer cell line SUM 159 cells were used in this study. The sources 
and culture conditions were described in Chapter 2 [72]. For experiments, FBS was 
reduced to 2%. For short term treatment (18 hrs), cells were plated at 1.5 x 10
5
 cells/12 
well for apoptosis, 3 x 10
5
/6 well for ALDH activity and 3 x 10
6
/100 mm dish for western 
blot analyses, respectively, referred as high cell density. For long term treatment (3 day), 
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cells were plated at 1 x 10
5
/6 well for ALDH activity and 1 x 10
6
/100 mm dish for 
western blot analyses, respectively, referred as low cell density. Cells were allowed to 
attach overnight before treatments. Vitamin E compounds were dissolved in 1:4 
DMSO/Ethanol at 40 mM as stock solution, respectively. Equivalent levels of 1:4 
DMSO/Ethanol was used as vehicle control (VEH).  
4.3.3 Quantification of apoptosis   
Apoptosis was quantified by Annexin V-FITC/PI assays following the 
manufacturer’s instructions. Fluorescence was measured using Fluorescence Activated 
Cell Sorter (FACS) analyses with a LSR Fortessa flow cytometer, and data were analyzed 
using FACSDiVa software (version 6.1.3) (BD Biosciences, San Jose, CA). Cells 
displaying phosphatidylserine on their surface (i.e. positive for annexin-V fluorescence) 
were considered to be apoptotic. 
4.3.4 Mammosphere formation assay 
Unsorted and sorted ALDH+ cells were assessed for ability to form 
mammospheres using established mammosphere formation conditions [30]. Briefly, cells 
were plated in 6-well ultra-low attachment plates at 100,000 cells/well under 
mammosphere formation conditions described in [30] followed by different treatments 
for 7 days. After counting the number of primary mammospheres, the mammospheres 
were disassociated into single cell suspensions and re-cultured for another 7 days without 
treatments to determine the number of secondary mammospheres. Then, the secondary 
mammosphere were disassociated and seeded back for another 7 days to determine 
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numbers of tertiary mammospheres. Counting of mammospheres were performed 
manually under 10 X magnification on an Olympus DL71 microscope.   
4.3.5 Analysis of aldehyde dehydrogenase activity and sorting of ALDH+ population 
ALDH activity was determined using an Aldefluor assay kit (Stem Cell 
Technologies, Inc, Vancouver, BC, Canada) according to the manufacturer’s instructions. 
Aldefluor fluorescence was detected by fluorescence activated cell sorting (FACS) using 
a FL1 detector in a LSR Fortessa flow cytometer and analyzed using BD FACSDiVa 
software (version 6.1.3). ALDH+ cells were sorted using a FACS Aria cell sorter (Becton 
Dickinson, Palo Alto CA). 
4.3.6 Western blot analyses 
  
Western blot analyses were conducted as described previously [72]. Primary 
antibodies to the following proteins were used in this study: pStat-3 and Stat-3 (Cell 
Signaling), c-Myc and Cyclin D1 (Santa Cruz Biotechnology, Santa Cruz, CA), and 
glyceraldehyde-3-phosphate drogenase (GAPDH, made in house). Secondary antibodies 
used included: horseradish peroxidase conjugated goat-anti-rabbit and rabbit-anti-mouse 
(Jackson Immunoresearch, Rockford, IL). 
4.3.7 Statistical Analysis  
The student’s t-test was used to determine statistical differences between 
treatment and control values. Differences were considered statistical significant at 





4.4.1 Both T3 and T3 induce apoptosis in SUM 159 TNBC cells. 
 Studies examined the ability of T3 or T3 to induce apoptosis in SUM 159 
human TNBC cells using Annexin V-FITC-FACS apoptotic procedures. Treatment of the 
TNBCs for 18 hours with T3 at 10 and 20 M or T3 at 5 and 7.5 M significantly 
increased apoptotic percentages in comparison to vehicle control (VEH) (Fig 4.1). 
Treatment of  human mammary epithelial cells (HMECs) with either 40 M T3 or T3 
did not induce apoptosis (data not shown), indicating that T3 or T3 selectively target 
cancer cells.  
 
Fig 4.1 Both T3 and T3 induce apoptosis in SUM 159 TNBCs. Cells were treated 
with different concentrations of T3 and T3 for 18 hours, followed by Annexin V/PI 
analyses to determine percentage of cells undergoing apoptosis. Data are depicted as 
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mean + S.D. of three individual experiments. * Statistically different from vehicle 
control, p<0.05.  
 
 
4.4.2  T3 or T3 reduce numbers of TICs in SUM 159 TNBC cells.  
 Studies investigated the ability of either T3 or T3 to reduce numbers of SUM 
159 TICs by conducting three-generation (serial) mammosphere formation assays as well 
as analyzing the numbers of ALDH+ cells, two well established procedures for assessing 
the  ability of treatments to reduce numbers of TICs [14, 15]. T3 at 1.25 and 2.5M 
significantly reduced the number of mammosphere forming cells in all three generations 
with T3 at 2.5 M eliminating all mammosphere forming cells by the third generation in 
comparison to vehicle control (Fig 4.2A). T3 at 0.625 M significantly reduced the 
number of mammosphere forming cells in the second and third mammosphere 
generations; whereas, T3 at 1.25, significantly reduced the number of mammosphere 
forming cells in all three generations (Fig 4. 2A).  
As an alternative approach, the ALDH activity assay was used to determine if T3 
or T3 eliminated ALDH+ population, an established TIC marker in SUM159 cells [18]. 
Treatment of unsorted SUM 159 cells for 18 hours with T3 at 15 M or T3 at 5 M 
significantly reduced numbers of ALDH+ cells in comparison to vehicle control treated 
cells (Fig 4.2B).  Furthermore, treatment of sorted ALDH+ TNBCs with low levels of 
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T3 or T3 eliminated the primary mammosphere forming cells in comparison to vehicle 





Fig 4.2 Both T3 and T3 eliminate TICs in SUM 159 TNBCs. Serial mammosphere 
formation assays were performed using unsorted SUM 159 cells cultured with different 
concentrations of T3 and T3 in the 7-day primary mammosphere formation assay. 
Secondary and tertiary mammosphere formation assays were conducted as described in 
the Materials and Methods section without further treatment. Mammospheres, using 
vehicle control as 100% are presented as mean ± S.D. of three individual experiments 
(A). Percentages of ALDH+ cells in unsorted population of SUM 159 cells treated for 18 
hours with different concentrations of T3 and T3 were determined by ALDH activity 
assay (B). Primary mammosphere formation assay was performed using 100 sorted 
ALDH+ cells/24 well, treated with different concentrations of T3 and T3 for 7 days 
(C). A, B and C data are presented as mean + S.D. of three individual experiments. 
*significantly different from VEH treatment, p<0.05.  
 
 
4.4.3  T3 or T3 suppress pStat-3 as well as Cyclin D1 and c-Myc protein levels in 
SUM 159 TNBC cells 
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Treatment of SUM 159 cells for 18 hours with either T3 or T3 reduced levels of 
pStat-3 as well as pStat-3 downstream mediators Cyclin D1 and  c-Myc (Fig 4.3).  
 
 
Fig 4.3 Both T3 and T3 suppress pStat-3, Cyclin D1 and c-Myc in SUM-159 
TNBCs.  Cells were treated with different concentrations of T3 and T3 for 18 hours, 
followed by western blot analyses to determine the protein levels pStat-3, tStat-3, Cyclin 
D1, and c-Myc in comparison with vehicle control. GAPDH was used as loading control. 








4.4.4   T or T induce apoptosis in SUM 159 TNBC cells.  
Next, we evaluated the in vitro pro-apoptotic effects of T and T using SUM159 
TNBC cells under both short term (18 hrs) and long term (3 days) treatment conditions. 
T and T treatments at different doses up-to 100 M for 18 hours did not induce 
apoptosis (Data not shown).   However, treatment with T3 and T3 for 3 days 




Fig 4.4 Both and T exhibit effects on induction of apoptosis in SUM-159 TNBCs. 
Cells were treated with T or T at 60 and 80 M for 3 days, followed by Annexin V/PI 
analyses to determine percentage of cells undergoing apoptosis. Data are depicted as 
mean + S.D. of three individual experiments. * Statistically different from vehicle 





4.4.5 Tocopherols exhibit different effects on TICs in SUM 159 TNBC cells.  
The effects of T, all-rac-T, T or T on TNBC ALDH+ populations were 
investigated using 18 hour treatments (Fig 4.5A) as well as three day treatments (Fig 
4.5B). T or T treatments of SUM 159 TNBCs at 40 M for 18 hours, respectively, 
significantly reduced the numbers of  ALDH+ cells; whereas, treatments with T or all-
rac-T at 40 M for the same time period significantly enhanced ALDH+ cells (Fig 
4.5A). Three days treatment of the SUM 159 cells with the same vitamin E compounds at 
10 or 20 M gave similar results as observed with the 18 hour treatment time period, i.e., 
T or T significantly reduced the numbers of ALDH+ cells while T or all-rac-T 
significantly increased ALDH+ cells in comparison to vehicle control (Fig 5B).  
Furthermore, T in a seven day mammosphere assay significantly reduced the number of 
primary mammosphere forming cells in unsortred SUM 159 cells (Fig 4.5C).  T at 20 
M significantly increased the number of mammosphere forming cells (Fig 4.5C), 
whereas, all-rac-T treatments at 10 and 20 mM enhanced the percentages of 
mammospheres, but not significantly different from vehicle control (Fig 4.5C).  Taken 
together, these data show that tocopherol compounds generate markedly different effects 








Fig 4.5 Tocopherol compounds exhibit different effects on TICs in SUM 159 TNBCs 
SUM 159 Cells were treated for 18 hours with 20 and 40 M T, all-rac-T, T and T, 
respectively (A). SUM 159 cells were treated for 3 days with these four vitamin E forms 
at 10 and 20 M (B). Following treatment, the percentage of ALDH+ cells in unsorted 
SUM 159 cells were determined using ALDH activity assay ( A and B). Sorted SUM 159 
ALDH+ cells were treated with 10 and 20 MT, all-rac-T or T for 7 days during the 
primary mammosphere formation assay as described in the Materials and Methods 
section (C). Data are presented as mean + S.D. of three individual experiments. 
*significantly different from VEH treatment, p<0.05. 
 
4.4.6 T and all-rac-T enhanced pStat-3 protein levels, while  T and T 
suppressed pStat-3 protein levels. 
 The effects of tocopherol treatments of SUM 159 cells on pStat-3, cyclin D1and 
c-myc proteins were evaluated by western blot analyses. Treatment of SUM 159 cells for 
three days with 10 or 20 M  T or all-rac-T increased pStat-3, c-Myc, and Cyclin D1 
protein levels in comparison to vehicle control (Fig 6A). Treatment of SUM 159 cells 
with 60 or 80 M T or T for three days suppressed pStat3, Cyclin D1 and c-Myc 







Fig 4.6  T and all-rac-T promote Stat-3 signaling in SUM 159 TNBCs while T 
and T suppress.   SUM 159 Cells were treated for 3 days with 10 or 20 M T and 
all-rac-T respectively (Fig A) or treated with 60 and 80 M T and T for 3 days (B), 
followed by western blot analyses to determine protein levels of pStat-3, tStat-3, c-Myc 
and Cyclin D1. GAPDH was used as loading control. Data are representative of two or 




There is growing evidence for the existence of TICs, which are a small subset of 
cells within a tumor, capable of self renewing and initiating/sustaining tumor growth 
[167,168]. TICs are a small subset of cells in tumors, i.e., 1% in colon cancer and 
leukemia and approximately 2% in breast cancer [169, 170 and 171].  Our study as 





The elimination of TICs provides a new opportunity for prevention and treatment 
of cancers, including human TNBC. In this regard, developing naturally occurring 
bioactive compounds that can target TICs as anticancer agent is highly significant for 
prevention of primary tumor and tumor recurrence. This study evaluated different vitamin 
E compounds for ability to eliminate TICs, and induce apoptosis in TNBCs.  Novel 
findings are: (i) Tocotrienols (T3 and T3) induce apoptosis in TNBC cells, but not 
normal mammary epithelial cells, suggesting selective toxicity of T3 and T3 for breast 
cancer cells. Although tocopherols (T and T) induce apoptosis in TNBC cells, their 
pro-apoptotic potency is lower than tocotrienols; in marked contrast, T or all-rac-T 
did not exhibit pro-apoptotic properties. (ii) Both tocopherol and tocotrienol  and 
compounds eliminated TICs, as demonstrated by their ability to reduce ALDH+ 
population and inhibit primary mammosphere formation of ALDH+ population. In 
contrast, T and all-rac-T increased the ALDH+ population,  and enhanced the 
percentage of mammosphere forming cells (iii)Both tocopherol and tocotrienol forms of 
 and suppressed pStat-3 as well as pStat-3 downstream targets c-Myc and Cyclin D1; 
whereas T and all-rac-T enhanced pStat-3 as well as Cyclin D1 and c-Myc protein 
levels.  Taken together, our in vitro data show that - and -tocopherols or tocotrienols 
possess the in vitro ability to eliminate TICs, while T and all-rac-T promote TICs, 
thereby showing that some, but not all, vitamin E have anticancer properties, and most 
importantly showing that T and all-rac-T have potential to promote cancer. Data also 
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show that Stat-3 signaling is involved in the differential effects of these different forms of 
vitamin E on TICs. 
Accumulating in vitro and in vivo data support the notion that - and -forms of 
tocopherols and tocotrienols are vitamin E forms that possess anticancer properties [56, 
57 and 58 ].  Previous data from our lab showed that T induced apoptosis in both MCF-
7 and SUM 159 cells [56]. Jiang and co-workers reported that both T and T induced 
apoptosis in prostate cancer cells [173]. In vitro data showed that tocotrienols have better 
pro-apoptotic properties than tocopherols [56]. Here, for the first time, we show that not 
only T3, but also T3, as well as T and T possess in vitro anti-TIC properties. Data 
show that T3 and T3 not only induce TNBCs to undergo apoptosis, but selectively 
eliminate TICs. Although T and T show less pro-apoptotic property they eliminate 
TICs. However, due to the differences in vivo bioavailability of different forms of 
vitamin E [174], these in vitro data provide the rational for evaluation of select 
tocopherols and tocotrienols for their in vivo anticancer actions.   
How T and T as well as T3 and T3 more selectively eliminate TICs is not 
known and worthy for further studies. TICs can be inhibited via different mechanisms, 
including inhibiting their self-renewal and differentiation capacity as well as triggering 
TICs to undergo apoptosis. TICs are highly resistant to apoptosis due to high expression 
of pro-survival pathway mediators [175]. Many targeted anticancer agents that activate 
pro-apoptotic pathways, but do not suppress pro-survival pathways, hardly have the 
ability to eliminate TICs [176]. While agents that can activate both pro-apoptotic 
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pathway and pro-survival pathways, such as chemotherapeutic drugs plus TRAIL, have 
the potential to stimulate TICs [176], suggesting that only agents that can both activate 
pro-apoptotic pathways and inhibit pro-survival pathways have the potential to eliminate 
TICs by apoptosis. Previous data from our lab showed that T3 and T3, as well as T 
induce apoptosis via activation of ER-mediated DR5 pro-apoptotic pathway [56]. In this 
study, data show that both - and - forms of tocopherol and tocotrienol suppress Stat-3 
survival pathway. Stat-3 has been shown to regulate survival mediators such as Bcl-xL, 
Bcl-2, Survivin, and c-FLIP. It has been reported that T suppresses c-FLIP and Survivin 
[177]. In addition, T3 has been reported to suppress Akt and NF-kB pro-survival 
mediators [65], suggesting that the ability vitamin E compounds, to activate pro-apoptotic 
pathways and to suppress pro survival mediators, may contribute to their ability to 
eliminate TICs via induction of apoptosis of TICs. Since c-Myc and Cyclin D1 are two 
important mediators for TIC renewal, we do not rule out the possibility that these  
vitamin E compounds eliminate TICs via inhibition of TIC renewal.  
Importantly, these studies demonstrate that T and all-rac-T increase the 
numbers of TNBC TICs. Although the in vitro findings may not correlate with in vivo 
results, these studies may provide the first clue to explain why the recently finished 
follow-up of SELECT analyses showed higher prostate cancer incidence in subjects 
receiving all-rac-51]. Our studies suggest further investigation of T and all-rac- 
for its cancer risk potential, especially since both are widely used as dietary supplement 
and food additives.   
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How T and all-rac- increase TICs is not known. Since our preliminary data 
show that the antioxidant N-acethyl cysteine (NAC) increased TNBC ALDH+ population 
as well as increased pState-3 protein levels (data not shown), our working hypothesis is 
that T and all-rac- promote TICs via their antioxidant properties. It has been 
reported that TICs are enriched under redox conditions [178], suggesting that redox is 
essential for maintaining TICs.  
To the best of our knowledge, this is the first report showing that T and all-rac-
 increase Stat-3 protein levels in TNBCs, which is in conflict with previously 
published data showing that antioxidants such as NAC and diphenyleneiodonium (DPI) 
block Stat-3 activation in Hela cells [179]. Further studies are needed to resolve this 
conflicting data.  
In summary, these data, for the first time, demonstrated that T3, T3, T and T, 
possess in vitro anti-TIC property in TNBCs, while T and all-rac-T exhibit the 
potential to promote TICs. Data also showed that suppression and activation of Stat-3 
signaling are associated with elimination of TICs in - and -forms of tocopherol and 








             Chapter 5 Summary and Future Directions 
5.1 Summary 
 
These studies investigated the anti-cancer properties of vitamin E compounds and 
DHA singly and in combination in human triple negative breast cancer cell lines.  
Chapter 2 studies investigated the anti-TNBC properties of highly unsaturated 
omega-3 fatty acid docosahexaeonic acid, a dietary component widely used as a 
supplement with established anti-inflammatory, cardioprotective and anti-cancer 
properties. Data in this chapter showed that DHA at physiologically relevant levels 
induced apoptosis in human TNBCs, but did not induce apoptosis in normal human 
mammary epithelial cells under the same experimental conditions. Investigations of 
DHA's mechanisms of pro-apoptotic actions in TNBCs revealed triggering of 
endoplasmic-reticulum stress mediated CHOP/DR5 pro-apoptotic events involving both 
caspase-8 and caspase 9, suggesting both extrinsic and intrinsic apoptotic signaling.  
Data also showed that reactive oxygen species were a necessary upstream mediator of 
DHA-induced apoptosis. Vitamin E in the form of RRR--tocopherol blocked DHA-
induced ROS formation as well as apoptotic events, indicating the potential for 
antagonistic effect of supplemental T on DHA’s anticancer actions. In contrast to T, 
vitamin E in the form of -tocotrienolexhibited anticancer activity and enhanced DHA-
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induced apoptosis. These data showed that DHA exhibited pro-apoptotic properties, T 
blocked DHA-induced apoptosis, and T3 enhanced DHA-induced apoptosis.    
Chapter 3 studies investigated the ability of DHA to eliminate TICs and the 
cooperative effects of T3. Novel findings in this study include: (i) DHA eliminated TICs 
as determined by the ability of DHA to reduce the ALDH+ population and to inhibit 
mammosphere formation, (ii) the ability of DHA to eliminate TICs was correlated with 
DHA's ability to reduce levels of pStat-3 as well as c-Myc and cyclin D1, (iii) siRNA to 
Stat-3 reduced the number of SUM 159 ALDH+ cells and reduced pStat-3, c-Myc, and 
cyclin D1, suggesting that Stat-3 is necessary for maintaining ALDH+ population and 
contributes to the expression of c-Myc and cyclin D 1, and (iv) T3 cooperatively 
enhanced DHA elimination of TICs and suppression of Stat-3 signaling. Taken together, 
these data provide in vitro evidence that DHA and DHA + T3 possess the potential to 
eliminate TICs from human TNBCs via suppression of Stat-3 signaling.  
Chapter 4 studies investigated the anticancer effects of several vitamin E 
compounds for ability to eliminate TICs and induce apoptosis in TNBCs. T3 and T3 
induced apoptosis in TNBCs, and importantly, had no adverse effects on normal human 
mammary epithelial cells, suggesting selective anti-cancer properties of these forms of 
vitamin E to TNBCs. In comparison with T3 and T3, T and T exhibited less pro-
apoptotic activity; whereas, T and synthetic vitamin E (all-rac-T) did not exhibit pro-
apoptotic properties. Furthermore, T and T as well as T3 and T3 eliminated TICs, as 
determined by their ability to reduce ALDH+ population and inhibit mammosphere 
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formation. In contrast, T and all-rac-T increased the ALDH+ population and 
promoted mammosphere formation, suggesting that these two forms of vitamin E 
enhance tumor progression rather than induce tumor suppression. - and -forms of 
tocopherols and tocotrienols suppressed pStat-3 and its downstream targets c-Myc and 
Cyclin D1; whereas, T and all-rac-T increased levels of Stat-3 signaling. In summary, 
these data showed that - and -forms of tocopherols and tocotrienols possess the in vitro 
ability to eliminate TICs; whereas, T and all-rac-T promote TICs, highlighting the 
fact that vitamin E forms exhibit quite different actions on cancer cells. Data also 
suggested that the Stat-3 signaling pathway is involved in the differential effects of 
different vitamin E compounds on TICs. 
 In summary, data presented in this dissertation showed that DHA and certain 
forms of vitamin E can induce apoptosis and eliminate TICs in TNBCs, and the 
combination of DHA + T3 at physiological levels enhances the anticancer actions, 
thereby, providing a novel strategy for using those nutrient-based compounds singly or in 
combination as effective non-toxic dietary cancer therapeutics.  In striking contrast, T 
showed potential to promote TICs and block DHA anticancer action, suggesting a 
potential negative impact of T on cancer prevention and treatment. These data provide a 




5.2 Future directions 
 
Study #1 In vivo verification of the anticancer effects of DHA and T3 singly 
as well as in combination. An important and necessary study before considering testing 
these two nutrients as anticancer agents in humans will be to test their anti-cancer 
properties in vivo by establishing TNBC tumors in the NOD/SCID pre-clinical xenograft 
mouse model and conducting a serial transplantation assay. End-points for efficacy 
evaluation would be to determine treatment ability to:  (i) reduce primary tumor volume 
and metastases, (ii) eliminate TICs in primary tumor by ex vivo testing of tumors from 
treated mice for reduced ALDH+ population and reduced ability to form primary, 
secondary, and tertiary mammospheres, (iii) to reduce tumor incidence of secondary and 
tertiary transplants, and (iv) evidence that treatment activated ER stress/CHOP/DR5 and 
suppressed Stat-3 signaling in the primary tumor. 
Study #2 In vivo verification of the effect of T and all-rac-T on promoting 
TICs and on inhibiting the anticancer action of DHA + T3. In vivo evidence that the 
combination of T3 and DHA are effective anticancer agents in vivo (i.e. expected 
outcome of Study #1) would provide the necessary data to test the ability of natural RRR-
-tocopherol) and synthetic vitamin E, the two most common forms of vitamin E taken 
as dietary supplements and used as food additives in the United States to promote TICs 
and to inhibit the anticancer actions of T3 and DHA in the NOD/SCID mouse model 
using the same methods as study#1. This is a critical study that has important significance 
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for the beneficial use of DHA and T3, and the harmful impact of RRR--tocopherol and 
synthetic vitamin E in the treatment of TNBC patients.  
Study #3. Identification of the key role of Stat-3 signaling in regulation of 
breast cancer TICs and identification of upstream activators of Stat-3. Data showed 
that DHA alone or in combination with T3 suppressed pStat3 pathway as a regulator of 
TIC in TNBCs, and that T and all-rac-T enhanced Stat3 signaling. Further studies are 
needed to determine if Stat-3 is necessary for the TIC blocking events and what up-
stream initiators of Stat3 signaling are involved in either the beneficial (anti-TIC) versus 
harmful (pro-TIC) actions of various vitamin E compounds. Overexpression and 
knockdown assays will need to be used to determine the role of Stat-3 in elimination of 
TICs by DHA and T3, as well as, by the combination of DHA + T3, and in promotion 
of TICs by T and all-rac-T, respectively. Preliminary data are presented below as well 
as relevant references to focus future studies on identification of upstream mediators of 
Stat-3. It has been reported that T3 suppresses pStat-3 via upregulation of protein-
tyrosine phosphatase - sarcoma (Src) homology phosphatase-1 (SHP-1), a phosphatase 
that inhibits the phosphorylation of Stat-3 by Janus family kinases (JAK) [180]. Stat-3 
also has been shown to cross-talk with NF-kB and PI3K/Akt pathways [181]. Preliminary 
data from our studies show that DHA and T3 alone and in combination suppressed 
phospho-IkB (p-IKB) and downstream mediators of NF-kB signaling pathway in two 
TNBC cell lines. Furthermore, DHA prevented the translocation of NF-kB subunit p65 
from the cytosol to the nucleus (Fig 5.1). Enhanced expression of SHP-1 has also been 
102 
 
observed in TNBCs treated with DHA and T3 alone or in combination (Fig 5.2). 
Therefore it will be of interest to determine if NF-kB and SHP-1 are upstream mediators 
of Stat-3 in these events. A diagram of the proposed signaling pathways is presented in 
Fig 5.3. 
 
Fig 5.1  DHA and in combination of T3 suppresses NF-kB pathway.  A. Western 
blot data show that Phospho-IkB (p-IkB) and NF-kB downstream mediators, c-FLIP, 
Survivin and Bcl-2 are suppressed by DHA, suggesting that DHA inhibits NF-kB 
pathway.  B. DHA suppresses P65 translocation of P65 from cytosol to nucleus, 
suggesting the ability of DHA to inhibit NF-kB activation. C. DHA in combination of 
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Fig 5.2 Upregulation of SHP-1 in MDA-MB-231 and SUM 159 cells Western blot 
show upregulation of SHP-1 with treatment of DHA alone (A) as well as in combination 




Fig 5.3 Proposed mechanisms of regulation of Stat-3 by NF-kB and SHP-1 Published 
and our present data show that DHA alone or in combination with T3 suppress NF-kB as 
well as downstream factors c-FLIP, Bcl-2 and survivin. Therefore, we propose that DHA 
alone  or in combination of T3 eliminate TIC in TNBCs via suppressing CSC pro-
survival mediator-pStat3 which is negatively regulated by SHP-1 and positively regulated 
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